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Abstract 
There has been large evidence that patients with psychotic disorders, such as schizophrenia, 
usually experience early signs of psychosis even before developing frank psychosis. In recent 
years, research into the field of early detection, in particular the identification of factors that 
increase disease risk, has received growing scientific and clinical interest. An intriguing re-
search area in this field is the investigation of gender differences. The present dissertation 
aims to investigate (1) gender differences in symptomatology, drug use, comorbidity (i.e. sub-
stance use, affective and anxiety disorders) and global functioning in patients with an at-risk 
mental state (ARMS) for psychosis, (2) sex differences in cognitive functioning in ARMS 
patients and healthy controls (HC), (3) gender differences in the first self-perceived signs and 
symptoms in ARMS and first-episode psychosis (FEP) patients.  
The first study demonstrated that gender differences in symptomatology and comorbidity in 
ARMS patients are similar to those seen in overt psychosis and in healthy controls. However, 
the observed differences were so small that they are probably not clinically meaningful. The 
second study showed that sex differences in cognitive functioning in ARMS are similar to 
those seen in healthy men and women. In particular, the female advantage in verbal learning 
and memory seems to be equally present in ARMS patients and HC. Our third study found 
only few and relatively small gender differences in the first self-perceived signs and symp-
toms. While men initially mainly noticed negative and cognitive symptoms, women first no-
ticed (sub-threshold) positive and affective symptoms.   
All in all, regarding emerging symptomatology and cognitive functioning, it seems that the 
above described differences between women and men – if present at all – are small and re-
semble those in the general population. Similarly, few gender differences were found regard-
ing first self-perceived signs and symptoms.  
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Early detection of psychosis
During the past two decades, there has been increasing interest in the early detection and in- 
tervention during the prodromal phase of a psychotic disorder. Patients often experience early 
signs of psychosis even 1 to 5 years prior to the first episode of frank illness (Riecher-Rssler 
et al., 2006). This delay in diagnosis and treatment has been described by two concepts,
namely the duration of untreated psychosis (DUP) and the duration of untreated illness (DUI). 
Regarding DUP, patients suffer from productive psychotic symptoms, such as hallucinations 
or delusions, for an average of 1 to 3 years prior to the diagnosis of psychosis and its first
treatment. DUI is a so-called Ôunspecific prodromal phaseÕ  which lasts on average 2 to 5 years
and already starts before DUP (Riecher-Rssler et al., 2006). The ABC study was one of the
first studies that could show this delay on a methodologically sound basis (H  fner et al., 1998;
Riecher et al., 1991). The results of this study suggest that the initial signs on average become
apparent approximately 4.6 years before first admission and diagnosis of schizophrenia 
whereas the first psychotic symptoms occur on average 2.1 year prior to first admission
(H  fner et al., 1993a). Another major finding of the ABC study was that mostpatients suffer 
from severe impairments and losses in numerous social domains such as independent living,
partnership, education or work even before first admission (H  fner et al., 1995a). A longer 
DUP can have severe consequences. It has been demonstrated that thedelay is associated with 
a worse long-term prognosis, worse overall functional outcome, lower levels of symptomatic
and functional recovery, negative symptom severity (Murru et al., 2018; Perkins et al., 2005),
poorer social functioning and treatment response (Perkins et al., 2005), stronger impairment
of psychological and social development (Riecher-Rssler  et al., 2006) and higher overall  
treatment costs (Lincoln et al., 1995; Ricciardi et al., 2008). Researchers and clinicians have 
therefore concentrated on the early detection and intervention of psychosis to improve the
course of the disease. To prospectively identify people at-risk for psychosis and capture the
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pre-psychotic phase, the construct of a clinical high-risk (CHR) state for psychosis has 
evolved (see Figure 1; Fusar-Poli et al., 2013). There have been two complementary sets of 
clinical features that have been used to diagnose the CHR state in individuals at-risk, namely 
ultra-high-risk (UHR) and basic symptoms (BS) criteria.  
The UHR criteria comprise four main sets of clinical criteria: Attenuated psychotic symptoms 
(APS), brief limited intermittent psychotic symptoms (BLIPS), genetic risk and deterioration 
syndrome (GRD), and unspecified prodromal symptoms (UPS). They were defined to identify 
young people at high risk of developing a first episode of psychosis (Fusar-Poli et al., 2013; 
Schultze-Lutter et al., 2015). Different interview measures have been developed to assess 
UHR features and to determine whether individuals meet criteria for UHR (for a detailed de-
scription of the UHR criteria and their assessment, see Fusar-Poli et al., 2013). Meta-
analytical findings confirm that the currently used interviews for psychosis prediction show 
an excellent overall prognostic performance, despite the significant differences in their criteria 
(Fusar-Poli et al., 2015). However, this excellent overall prognostic performance was mainly 
mediated by an outstanding ability of the instruments to rule out psychosis, at an expense of 
their ability to rule in psychosis (Fusar-Poli et al., 2015). 
BS are subjectively experienced disturbances of different domains, including perception, 
thought processing, language and attention (Fusar-Poli et al., 2013; Schultze-Lutter, 2009). 
They were developed to identify the risk for psychosis even before functional impairment 
appeared (Schultze-Lutter et al., 2010). BS were originally assessed using the Bonn Scale for 
the Assessment of Basic Symptoms (BSABS, Klosterkötter et al., 1997). More recently, the 
Schizophrenia Proneness Instrument, Adult version (SPI-A, Schultze-Lutter et al., 2007), and 
the self-report Frankfurt Complaint Questionnaire (FCQ) have mainly been used (Uttinger et 
al., 2018). 
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Figure 1. Model of psychosis onset from the clinical high-risk state. The higher the line on 
the y-axis, the higher the symptom severity (Fusar-Poli et al., 2013) 
 
BS: Basic Symptoms; APS: Attenuated Psychotic Symptoms; BLIP: Brief Limited Intermittent Psychotic episode. 
 
Those who meet the at-risk criteria either by UHR or BS are termed “Clinical High-Risk” 
(CHR) or “At-Risk Mental State” (ARMS) patients. Patients who meet UHR criteria only are 
termed  “Ultra-High-Risk” (UHR) patients (Fusar-Poli et al., 2012a). For this thesis, the term 
ARMS will be used to show that these individuals are already suffering from some symptoms 
and problems. It has been shown that less than 40% of patients identified as being in an 
ARMS will actually develop a psychotic disorder (Fusar-Poli et al., 2013). Independent of the 
psychometric instruments used, the mean (95% CI) transition risk to a full psychotic episode 
has been estimated as follows: 13% (8%-19%) at 6 months of follow-up, 16% after 1 year, 
22% after 2 years, and 47% after 3 years, 47% after t 4 years (Fusar-Poli et al., 2012b; Fusar-
Poli et al., 2016). Several risk factors have been detected to predict the conversion to psycho-
sis, including the age of ARMS patients (Fusar-Poli et al., 2012b), severity of attenuated posi-
tive psychotic symptoms (Oliver et al., 2019), low global functioning (Oliver et al., 2019), 
severity of negative psychotic symptoms (Oliver et al., 2019), impairments in cognitive func-
4
     
tioning (Fusar-Poli et al., 2012c), alterations in structure (Fusar-Poli et al., 2012d; Fusar-Poli 
et al., 2011), function (Fusar-Poli et al., 2007; Smieskova et al., 2010), connectivity (Crossley 
et al., 2009) and neurochemistry (Fusar-Poli et al., 2007; Smieskova et al., 2010) of the brain. 
However, it is still not possible to predict who will transition to psychosis and who will not 
(Oliver et al., 2019). Antipsychotic medication showed efficacy in reducing the rate of transi-
tion to psychosis by 45% (van der Gaag et al., 2013). However, such treatments are associated 
with high attrition rates (van der Gaag et al., 2013). Thus, the aim of several research projects 
in this area is to detect potential risk factors that modify risk of transition and improve the 
identification of patients at risk. Data for this dissertation was obtained from two early detec-
tion studies, namely the FePsy (Früherkennung von Psychosen = early detection of psycho-
sis) study and the EU-GEI (EUropean network of national schizophrenia networks studying 
Gene-Environment Interactions) study.   
 
 
     
 
    
 
 
  
   
Sex and gender differences
In the last few decades, a growing number of studies have addressed sex and gender differ- 
ences in almost all areas of health and well-being (Oertelt-Prigione et al., 2012; Riecher- 
Rssler,  2017; Schiebinger et al., 2016). For example in psychiatry, differences exist regard- 
ing prevalence, symptomatology, risk factors and influencing factors or course (Riecher- 
Rssler,  2010a; Riecher-Rssler,  2017). There is no doubt that sex and gender interact strong- 
ly and influence mental well-being as well as psychiatric disorders and diagnoses (Riecher- 
Rssler , 2010a). However, an import aspect to consider is the conceptual difference of sex 
and gender. While sex is a biologically reduced and dichotomous term, gender refers to psy- 
chosocial and cultural influences (measured by a questionnaire) (Ittig et al., 2015; Riecher- 
Rssler  et al., 2018). Thus far, women are still under-represented in research and several stud- 
ies still do not report results by sex and/or gender (Riecher-Rssler et al., 2018; Peters et al.,
2018). This also applies to schizophrenia research. Only half of all studies on schizophrenia
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up to 2010 reported sex and solely 2.5% analysed their findings in relation to sex (Barker-
Collo et al., 2011; Riecher-Rössler et al., 2018). This lack of research is surprising since ex-
planations of sex and gender differences may help us to elucidate pathogenic mechanisms that 
are particular to women or men. Furthermore, such findings would likely improve our treat-
ment and prevention strategies.  
 
FePsy study 
The FePsy study is an open prospective clinical study that aims to facilitate and improve the 
early detection of beginning psychoses (Riecher-Rössler et al., 2007). The study design is 
presented in Figure 2.  
 
 
 
BSIP: Basel Screening Instrument for Psychosis; BPRS: Brief Psychiatric Rating Scale.  
 
Study participants were recruited via the FePsy Clinic at the Psychiatric Outpatient Depart-
ment of the University Hospital Basel, which aims to identify patients in the early stages of a 
beginning psychotic disorder and to assess the risk of developing psychosis (Riecher-Rössler 
et al., 2007). Most referrals came from the own Psychiatric Outpatient Department, which 
serves an area of about 200 000 inhabitants but there were also some referrals from mental 
health professionals (e.g. general practitioners, psychiatrists etc.), from relatives or from the 
subject. All participants were screened with the Basel Screening Instrument for Psychosis 
Figure 2. Design of the FePsy study (Riecher-Rössler et al., 2007)
6
     
(BSIP) (Riecher-Rössler et al., 2008). The BSIP includes the four psychosis items of the Brief 
Psychiatric Rating Scale (BPRS, expanded version; Lukoff et al., 1986; Ventura et al., 1993) 
to rate (pre-) psychotic phenomena. The BSIP criteria corresponds closely to the Personal 
Assessment and Crisis Evaluation (PACE) inclusion/exclusion criteria (Yung et al., 1998). 
However, the BSIP additionally permits the inclusion of patients who only exhibit a combina-
tion of certain unspecific risk factors and indicators such as prodromes or marked social de-
cline (Riecher-Rössler et al., 2007). For a detailed description of the inclusion/exclusion crite-
ria and the criteria for transition of psychosis, see Riecher-Rössler (2007). All included pa-
tients had to undergo an extensive entry examination comprising potential risk factors for 
transition to psychosis, including systematic assessment of present and previous psycho-
pathology, neuropsychological testing, analyses of different blood parameters and neuroimag-
ing (i.e. resting state electroencephalography [EEG] and structural magnetic resonance imag-
ing [MRI]) (Riecher-Rössler et al., 2007). Each ARMS participant was followed-up at regular 
intervals for up to 5 years to evaluate whether they transition to frank psychosis (ARMS-T) or 
not (ARMS-NT). During the first year of follow-up, they were assessed monthly. During the 
second and third years, they were assessed 3-monthly and thereafter once a year (Riecher-
Rössler et al., 2007).  
 
 
 
 
 
   
  
EU-GEI study
The EU-GEI study is a naturalistic prospective multicentre study that aims to identify the in- 
teractive genetic, clinical and environmental determinants of schizophrenia (Kraan et al., 
2018). Several work packages from multiple disciplines are involved to address the current
challenges in Gene-Environment (G !  E) research. The general approach and overview of the 
European Network of National Networks studying Gene-Environment Interactions in Schizo- 
phrenia can be found elsewhere (van Os et al., 2014). Study participants were recruited from
11 Early Detection and Intervention Centers:nine in Europe (London, Amsterdam, The
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Hague, Vienna, Basel, Cologne, Copenhagen, Paris, Barcelona), one in Brazil (Saõ Paulo), 
and one in Australia (Melbourne). They were referred to the early detection centers by prima-
ry health care services, mental health professionals or from the subject or their family. Control 
participants were recruited by 4 of the above-mentioned centers: the Institute of Psychiatry, 
Psychology and Neuroscience (IoPPN) in London, the Personal Assessment and Crisis Evalu-
ation (PACE) clinic in Melbourne, the Amsterdam Medical Center (AMC) and Parnassia The 
Hague. They were approached by telephone and through advertisements at educational insti-
tutes. In Melbourne, controls were additionally approached at community cen-
ters/noticeboards and advertised via online platforms. All individuals were screened with the 
Comprehensive Assessment of At-Risk Mental States (CAARMS) (Yung et al., 2005). The 
CAARMS was designed to determine if an individual meets ARMS status and to measure 
other symptoms thought to indicate imminent development of a first-episode psychotic disor-
der (see Table 1).  
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BLIPS: Brief Limited Intermittent Psychotic Symptoms; CAARMS: Comprehensive Assessment of At-Risk Mental 
States; GAF: Global Assessment of Functioning; UHR: Ultra High Risk.  
 
A detailed description of the inclusion/exclusion criteria for ARMS and HC can be found in 
publication 2 of the present dissertation. All participants selected for the study had to undergo 
a multi-domain assessment at entry including several clinical scales/interviews, neuropsycho-
logical testing, analyses of blood parameters and neuroimaging (i.e. MRI). ARMS patients 
were followed at regular intervals for up to 2 years. Clinical outcome measures were assessed 
at baseline, 6 months (only brief assessment), 12 months and 24 months after baseline to de-
tect actual transition to psychosis.  
 
 
 
Table 1. CAARMS-defined ultra high risk and psychotic disorder threshold criteria (Yung et
al., 2005)
9
     
Theoretical Background 
Sex and gender differences in schizophrenia and emerging psychosis 
Sex and gender differences in schizophrenia have been described for many decades. Krae-
pelin had already reported that women are older at first admission for dementia praecox com-
pared to men (Kraepelin, 1919/1987). This finding has consistently been shown in many stud-
ies (Eranti et al., 2013). Differences between men and women with schizophrenia have also 
been described in other features of the illness, including incidence, prevalence, symptomatol-
ogy, course and in the response to treatment (Riecher-Rössler et al., 2018; Riecher-Rössler et 
al., 2010b; Ochoa et al., 2012; Abel et al., 2010). However, findings on sex and gender differ-
ences are mostly inconsistent. Many studies suffer from methodological problems, such as 
different patient groups (FEP, first episode schizophrenia, or chronic patients), confounding 
effects of antipsychotic medication, a lack of a systematic and homogenous assessment and a 
lack of statistical power. Furthermore, some results are based on selected help-seeking patient 
groups rather than on representative populations-based samples. This does not allow drawing 
valid conclusions on true sex and gender differences (Riecher-Rössler et al., 2018). Therefore, 
it is essential to describe consistent differences to understand the underlying causes in schizo-
phrenia. The aim of this thesis was to focus on clinical aspects of sex and gender differences 
in emerging psychosis to better understand the different pathogenesis in women and men 
leading to psychosis.  
 
 
Symptomatology, drug use, comorbidity and functioning
Findings regarding gender differences in psychopathological symptoms are less conclusive. It 
has often been reported that men have more severe negative symptoms, while women show 
more severe affective and specific psychotic symptoms (Riecher-Rssler et al., 2018). How- 
ever, many of these studies are based on selected populations rather than on representative
community-based populations. In the ABC study, which examined a representative communi-
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ty-based sample of first-episode patients, only few gender differences in psychopathology 
were found, and these were not significant after correction for multiple testing (Häfner et al., 
1991; Häfner et al., 1993a). With regard to substance abuse, recent studies in representative 
first-episode populations suggest that men have a higher prevalence of substance abuse (main-
ly cannabis and alcohol) (Riecher-Rössler et al., 2018; Abel et al., 2010; Ochoa et al., 2012). 
It has been assumed that the greater prevalence of substance abuse in men might have con-
tributed to gender differences in symptomatology, which many studies did not control for 
(Riecher-Rössler et al., 2018). In the general population, there are similar differences in 
symptomatology between men and women (Seedat et al., 2009). Studies examining gender 
differences in premorbid and social functioning have found higher functioning in women. 
This was shown in first-episode psychosis but also during the later course of the disease 
(Riecher-Rössler et al., 2018; Ochoa et al., 2012).     
 
 
 
   
  
 
 
 
So far, there are only few methodologically sound studies on gender differences in psycho- 
pathology of ARMS individuals. These studies have thus far yielded inconsistent results. In 
the comprehensive review of Barajas et al. (2015) many studies reported no gender differ- 
ences in ARMS patients, while others reported more negative symptoms and worse psychoso- 
cial functioning in men. A previous study of our own group in ARMS and FEP patients
showed more positive psychotic symptoms in women and more negative symptoms in men
(Gonzalez-Rodriguez et al., 2014). However, the differences did not withstand correction for
multiple testing. More recent studies reported similar small gender differences.While some
found more depression and social anxiety (Rietdijk et al., 2013; Pruessner et al., 2017) and 
more unusual perceptual experiences (Waford et al., 2015) in women, others reported more 
negative symptoms (Rietschel et al., 2015), disorganized communication (Theodoridou et al.,
2019) and violent behaviour (Tseliou et al., 2017) in men. In contrast, no gender differences
regarding symptoms were found by Kotlicka-Antczak et al. (2016). However, most of these
studies had not corrected for confounding variables or multiple testing. A recent review pub- 
11
     
lished by Riecher-Rössler et al. (2018) suggests that gender differences in the symptomatolo-
gy of patients at risk are small and comparable to those seen in the general population. Thus, 
in a representative worldwide general population sample of 72,933 subjects, men in general 
had more externalizing and substance disorders, while women had more anxiety and mood 
disorders (Seedat et al., 2009).  
In addition to the at risk signs and symptoms for psychosis, available evidence suggests that 
many ARMS patients have comorbid nonpsychotic disorders, in particular anxiety disorders 
and depression (Albert et al., 2018; Fusar-Poli et al., 2014). Fusar-Poli and colleagues (2014) 
performed a meta-analysis in 1,683 at risk patients and confirmed that baseline prevalence of 
comorbid depressive and anxiety disorders is 41% and 15%, respectively. To the best of our 
knowledge, only two studies have investigated gender differences in comorbid depressive and 
anxiety disorders in ARMS patients at baseline. In a recently conducted study of 764 ARMS 
patients (women, n = 329; 43%) from the North American Prodrome Longitudinal Study 
(NAPLS-2) a significantly higher lifetime prevalence of depression was observed in women 
compared to men (64% vs. 56%) (Kline et al., 2018). However, no significant gender differ-
ences with respect to depression and anxiety disorders were found in the study of Rietschel et 
al. (2015).  
To further elucidate these issues, the goal of the first study was to investigate gender differ-
ences in symptomatology, drug use, comorbidity and global functioning in a large multina-
tional sample of ARMS patients. Based on the above-mentioned previous research, we ex-
pected to find no significant differences between ARMS men and women.  
 
 
 
  
Cognitive functioning
The impairment of cognitive functioning is recognized as a core feature of schizophrenia and
an important predictor of outcome (Kahn et al., 2013). Several studies have shown that neu- 
rocognitive deficits are already present in patients with an ARMS for psychosis (Hauser et al.,
 12
     
2017; Pflueger et al., 2007). In addition, it has been found that ARMS patients with later tran-
sition to psychosis perform worse in tests measuring attention/vigilance, speed of processing, 
verbal and visual learning, and current and premorbid IC compared to those without transition 
(Hauser et al., 2017). It has been consistently reported that the prediction of psychosis can be 
improved by including neurocognitive performance measures into multivariable risk predic-
tion models (Hauser et al., 2017; Studerus et al., 2016; Riecher-Rössler et al., 2009; Riecher-
Rössler et al., 2017; Michel et al., 2014).   
 
 
 
 
          
 
 
 
 
 
 
 
 
Sex differences in cognitive functioning are well documented in healthy individuals. In gen- 
eral, women tend to perform better than men in tasks measuring verbal abi lities, whereas men
outperform women on visual-spatial tasks (Halpern, 2004; Miller  et al., 2014; Riecher-Rssler
et al., 2018). Similar sex differences regarding neurocognition were found in patients with 
schizophrenic psychoses (Riecher-Rssler et al., 2018; Mendrek et al., 2016). Many studies
have shown that women with schizophrenia have a better performance in verbal learning and
memory (Riecher-Rssl er et al., 2018; Bozikas et al., 2010; Zhang et al., 2012), whereas men
showed a better performance in tests of reaction time, visual memory and executive functions
(Riecher-Rssler  et al., 2018; Ittig et al., 2015). However, sex differences in cognitive func- 
tioning in schizophrenic psychosis remain equivocal. Inconsistencies might partly be due to
methodological differences as described previously. Considering ARMS patients, sex differ- 
ences in cognitive functioning have received considerable attention in recent years. A meta- 
regression analysis based on 19 studies assessing neuropsychological performance in ARMS
patients and HC showed a trend-level significance effect of sex on cognitive performance in 
ARMS patients, with females performing relatively better than males (Fusar-Poli et al.,
2012c). A previous study of our own group found that women perform better in the domain of
verbal learning and memory, while men showed a shorter reaction time during the working 
memory task (Ittig et al., 2015). However, no study has yet investigated sex differences in 
cognitive functioning in a large multinational sample of ARMS patients by using an extended
13
     
neuropsychological battery and a healthy comparison group. We therefore examined sex-
related cognitive performance differences in ARMS and HC subjects and whether sex differ-
ences vary between the investigated groups. Based on previous research, we expected a better 
performance of women in the domain of verbal learning and memory irrespective of group.     
 
 
 
 
 
   
 
 
 
  
  
  
    
 
  
First self-perceived signs and symptoms
The early prodromal phase of schizophrenia is characterized by unspecific symptoms. Sub- 
jects often realize that something is Ô wrongÕ — even years before fulfilling  diagnostic criteria 
for a psychotic disorder. During the prodrome, deficits concerning cognition, perception and
stress reactivity as well  as depressive and negative symptoms have often been reported
(H fner et al., 1998; H fner et al., 1995a; Iyer et al., 2008). These individually noticed chang- 
es will  subsequently be referred to as Ô first self-perceived symptoms’. As mentioned above, 
many studies have investigated the current psychopathological symptoms in ARMS and FEP 
patients, but only few studies have retrospectively assessed the very first self-perceived symp- 
toms at the onset of the disease. One of the first was the ABC study, which assessed first self- 
perceived symptoms in FEP patients (using the Instrument for the Retrospective Assessment
of the Onset of Schizophrenia (IRAOS)) and found that female FEP patients most frequently 
reported restlessness, depression and worrying, while men reported trouble with thinking, 
concentration and anxiety as their initial symptoms (H  fner et al., 1993a, H  fner et al.,
1993b). Iyer et al. (2008) examined first self-perceived signs and symptoms retrospectively
reported by 128 individuals with first-episode psychosis and found symptoms of depression 
and anxiety to be the most frequent signs and symptoms. However, the authors did not report
any gender-specific  early signs and symptoms. An earlier study of our own group compared
first self-perceived signs and symptoms independent of gender in ARMS, FEP and depressive 
disorder patients (Aston et al., 2012). ARMS patients reported Ôlos s of energyÕ  and Ôdiffic ul- 
ties concentratingÕ as first self-perceived signs and symptoms whereas FEP patients reported
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‘depression’ and ‘irritability’. There was much overlap of the first self-perceived signs and 
symptoms between the three groups.  
Although a few studies have retrospectively assessed the very first self-perceived signs and 
symptoms at illness onset, no study has yet examined ARMS and FEP patients together. Thus, 
the goal of the third study was to investigate the very first self-perceived signs and symptoms 
in male and female ARMS and FEP patients. Based on the above-described literature, we hy-
pothesized that overall only small gender differences would be observable in the first self-
perceived signs and symptoms of ARMS and FEP patients.  
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A B S T R A C T
Background: Gender differences in symptomatology in chronic schizophrenia and first episode psychosis
patients have often been reported. However, little is known about gender differences in those at risk of
psychotic disorders. This study investigated gender differences in symptomatology, drug use,
comorbidity (i.e. substance use, affective and anxiety disorders) and global functioning in patients
with an at-risk mental state (ARMS) for psychosis.
Methods: The sample consisted of 336 ARMS patients (159 women) from the prodromal work package of
the EUropean network of national schizophrenia networks studying Gene-Environment Interactions
(EU-GEI; 11 centers). Clinical symptoms, drug use, comorbidity and functioning were assessed at first
presentation to an early detection center using structured interviews.
Results: In unadjusted analyses, men were found to have significantly higher rates of negative symptoms
and current cannabis use while women showed higher rates of general psychopathology and more often
displayed comorbid affective and anxiety disorders. No gender differences were found for global
functioning. The results generally did not change when corrected for possible cofounders (e.g. cannabis
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use). However, most differences did not withstand correction for multiple testing.
Conclusions: Findings indicate that gender differences in symptomatology and comorbidity in ARMS are
similar to those seen in overt psychosis and in healthy controls. However, observed differences are small
and would only be reliably detected in studies with high statistical power. Moreover, such small effects
would likely not be clinically meaningful.
© 2019 Published by Elsevier Masson SAS.
1. Introduction
Gender differences in schizophrenia have attracted the
attention of scientific research for more than a century. Kraepelin
had already reported that women are older at first admission for
dementia praecox compared to men [1]. Most studies to date
confirm these findings [2]. Findings on severity of psychopatho-
logical symptoms are less conclusive, with some authors
suggesting that men have more severe negative symptoms
while women show more severe affective and specific psychotic
symptoms [2]. However, only few gender differences in
psychopathology of first episode schizophrenia were found in
the ABC study, and these were not significant after correction for
multiple testing [3,4]. With regard to substance abuse, available
evidence suggests that men have a higher prevalence of
substance abuse and higher levels of comorbidity compared to
women. Additionally, studies examining gender differences in
premorbid and social functioning have found higher functioning
in women [2].
In the past two decades, the field of early detection of
psychosis has received growing scientific and clinical interest [5],
albeit that only few methodologically sound studies have
considered gender differences in patients with an at-risk mental
state (ARMS) for psychosis. These studies have thus far yielded
inconsistent results. With regard to symptomatology, most
studies described in the comprehensive review of Barajas et al.
[6] reported no gender differences in ARMS patients. Neverthe-
less, some studies found more severe negative symptoms in men,
and other studies found lower levels of social functioning and a
longer duration of untreated illness in men compared to women
[6]. A more recent review published by Riecher-Rössler et al. [2]
suggests that gender differences in the symptomatology of
patients at risk are small and comparable to those seen in the
general population. Thus, in a representative worldwide general
population sample of 72,933 subjects, men in general had a
greater propensity to substance, alcohol and cannabis abuse,
while women had more affective symptoms, depression and
anxiety [7].
In addition to the at-risk signs and symptoms for psychosis,
many ARMS patients suffer from comorbid non-psychotic mental
disorders, in particular depression and anxiety disorders [8,9]. To
our knowledge, only two studies have investigated gender
differences in comorbid depressive and anxiety diagnoses in
ARMS patients at baseline. Kline et al. [10] examined a cohort of
764 ARMS patients (women, n = 329; 43%) from the North
American Prodrome Longitudinal Study (NAPLS-2), and observed
a significantly higher lifetime prevalence of depression in women
than men (64% vs. 56%). No significant gender differences in
comorbid affective and anxiety disorders were observed in the
study of Rietschel et al. [11].
To further elucidate these issues, the present study investi-
gated gender differences in symptomatology, drug use, comor-
bidity (i.e. substance use, affective and anxiety disorders) and
global functioning in a large multinational sample of ARMS
patients. Based on previous and our own findings, we expected
to find no significant differences between ARMS men and
women.
2. Methods
2.1. Setting and recruitment
The data analysed in this study were collected within the
multicenter EUropean Gene-Environment Interactions (EU-GEI)
study, from May 1, 2010 to April 30, 2015. The aim of EU-GEI study
is to identify the interactive genetic, clinical and environmental
determinants of schizophrenia [12]. The overall design of the
study was naturalistic, longitudinal and prospective, consisting of
a baseline and two follow-up time points. For the current
analyses, only baseline, i.e. at intake into the study, data were
used and only patients with complete data on cannabis frequency
were included.
ARMS patients were recruited from 11 Early Detection and
Intervention Centers, nine in Europe (London, Amsterdam, The
Hague, Vienna, Basel, Cologne, Copenhagen, Paris, Barcelona), one
in Brazil (Saõ Paulo), and one in Australia (Melbourne). Referrals
were accepted from primary health care services, mental health
professionals, or from the subject or their family. Study intake
corresponds to the admission date in the early detection service.
All participants were screened with an inclusion/exclusion
checklist (see below).
The protocol of the EU-GEI study was approved by the
institutional review boards of all study sites. EU-GEI was
conducted in accordance with the Declaration of Helsinki. The
Medical Ethics Committees of all participating sites approved the
study protocol.
2.2. Inclusion and exclusion criteria
Inclusion criteria for EU-GEI were: aged 18–35; being at-risk for
psychosis as defined by the Comprehensive Assessment of At-Risk
Mental State (CAARMS) [13]; adequate language skills local to each
center; and consent to study participation.
The exclusion criteria were: prior experience of a psychotic
episode of more than 1-week as determined by the CAARMS [13]
and Structural Clinical Interview for DSM Disorders (SCID) [14];
previous treatment with an antipsychotic for a psychotic episode;
and IQ < 60.
2.3. Determination of ARMS status
The CAARMS, used to identify ARMS patients [13], is a semi-
structured interview that encompasses psychotic symptoms and
a range of other psychopathological symptoms occurring in
emerging psychotic disorder. Individuals were classified as
being in an ARMS for psychosis if they met at least one of the
following risk criteria: (i) Vulnerability Group (a first-degree
relative with a psychotic disorder or diagnosed with schizotypal
personality disorder in combination with a significant drop in
functioning); (ii) Attenuated Psychotic Symptoms (APS) (psy-
chotic symptoms sub-threshold either in intensity or frequen-
cy); (iii) Brief Limited Psychotic Symptoms (BLIPS) (recent
episode of brief psychotic symptoms that spontaneously
resolved within 1 week). The full criteria can be found in Yung
et al. [13].
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2.4. Assessment of sociodemographic characteristics and medication
Sociodemographic characteristics were obtained using the
modified Medical Research Council (MRC) sociodemographic
schedule [15]. Data on psychiatric medication were assessed with
a medical history questionnaire, designed by the EU-GEI group.
2.5. Assessment of psychopathology
Psychopathological symptoms were assessed using the
expanded version of the Brief Psychiatric Rating Scale
(BPRS-E) [16], the Scale for the Assessment of Negative
Symptoms (SANS) [17], the Comprehensive Assessment of
At-Risk Metal State (CAARMS) [13], the Montgomery-Åsberg
Depression Rating Scale (MADRS) [18], and the Young Mania
Rating Scale (YMRS) [19]. Genders differences were investi-
gated using the following subscales:
BPRS-E: Activation, Positive symptoms, Negative symptoms,
Affect, Disorganization as defined by Shafer et al. [16] and the total
score
SANS: Affective Flattening, Alogia, Asociality-Anhedonia, Avo-
lition-Apathy, Inattention and the total score [17]
CAARMS: Behavioral change, Cognitive change - attention/
concentration, Emotional disturbance, Motor/physical
changes, Negative symptoms, Positive symptoms, General
Psychopathology[20]
MADRS: Detachment, Negative Thoughts, Neurovegetative,
Sadness as defined by Quilty et al. [21] and the total score
YMRS: Total score [19]
2.6. Assessment of comorbidity, drug use and functioning
Affective and anxiety disorders were assessed with the
Structured Clinical Interview for the Diagnostic Manual of
Psychiatric Disorders-IV (DSM-IV/SCID) [14]. Current use, abuse
and dependence of cannabis, amphetamine (e.g. speed, ecstasy),
cocaine, and hallucinogens (e.g. lysergic acid diethylamide (LSD),
“magic mushrooms”) were assessed using the Cannabis Experience
Questionnaire [22]. For cannabis, the frequency of use was
additionally assessed. Participants were defined as being current
users of a substance if they identified themselves as such or if they
reported any use in the preceding month.
The general level of functioning was assessed with the
GAF scale [23].
2.7. Statistical analyses
All statistical analyses were carried out using R environment for
statistical computing [24]. Because observations were non-
independent, that is, observations from the same center were
more similar than observations from different centers, gender
differences were analysed using mixed effects models including
gender as a fixed effects factor and randomly varying intercepts per
center to account for the clustering in the data. We used linear
mixed effects models for continuous measures (i.e. age, years of
education, functioning and psychopathology scales), mixed effects
logistic regression models for binary measures (i.e. psychiatric
diagnoses, drug use and psychiatric medication), ordinal mixed
effects models for ordered categorical measures (i.e. cannabis
frequency and highest level of education) and mixed effects
multinomial logistic regression for unordered categorical meas-
ures (i.e. living situation). We analysed gender differences in the
frequency of use of antipsychotics, antidepressants and hypnotics.
Cannabis frequency and age were included as covariates in models
estimating gender differences in psychopathology and living
situation, respectively. Continuous dependent variables were
z-transformed before inclusion to models and gender was included
as a binary variable with 0 and 1 describing men and women,
respectively. Thus, the regression coefficient for gender
described the standardized mean difference of women compared
to men. P-values were adjusted for multiple testing across all of the
63 gender differences tests using the False Discovery Rate (FDR)
procedure [25].
3. Results
3.1. Sample description
In total, 345 ARMS patients participated in the EU-GEI study. The
sample of this study consisted of 336 ARMS patients (177 men, 159
women). 9 ARMS patients had not complete data on cannabis
frequency and were excluded. Sociodemographic and clinical
characteristics are presented in Table 1. Male patients were
significantly older than female patients in unadjusted analyses
(P = 0.011). The significance of this effect disappeared after
correction for multiple testing (P = 0.175). There were no significant
gender differences in ARMS patients with regard to years of
education, highest level of education, living situation and current
psychiatric medication.
Table 1
Sociodemographic and clinical characteristics.
Men (n = 177) Women (n = 159) N P-value uncorrected P-value correcteda
Age 22.8 (5.13) 22.0 (4.70) 336 0.011* 0.175
Years of education 14.4 (3.29) 14.4 (2.84) 301 0.190 0.471
Highest level of education 296 0.987 1.000
School, no qualifications 16 (9.88%) 11 (8.21%)
School, with qualifications 51 (31.5%) 47 (35.1%)
Tertiary, Further 50 (30.9%) 38 (28.4%)
Vocational 24 (14.8%) 17 (12.7%)
Higher (undergraduate) 18 (11.1%) 17 (12.7%)
Higher (postgraduate) 3 (1.85%) 4 (2.99%)
Living with 336 0.575 0.471b
Alone 28 (15.8%) 23 (14.5%)
Other 56 (31.6%) 61 (38.4%)
Parents/family 93 (52.5%) 75 (47.2%)
Antipsychotics currently 15 (10.3%) 15 (11.3%) 279 0.911 0.988
Antidepressants currently 41 (28.1%) 43 (32.3%) 279 0.909 0.988
Hypnotics currently 2 (1.37%) 2 (1.50%) 279 0.994 1.000
Continuous variables are described by means and standard deviations in parentheses.
a P-value corrected for multiple testing.
b P-value corrected for age and multiple testing.
* P < 0.05.
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3.2. Gender differences in symptomatology and functioning
Table 2 shows the results of the linear mixed effects models
using symptomatology as continuous dependent variable and
gender as fixed effects factor. Standardized mean differences
(SMD) and 95% confidence intervals of the psychopathological
syndrome scales are additionally presented in Fig. 1.
Female ARMS patients showed significantly less severe BPRS
“Negative Symptoms” (b = !0.22, P = 0.046), more CAARMS
“General psychopathology” (b = 0.30, P = 0.007) and trendwise less
SANS “Affective Flattening” (b = !0.20, P = 0.073) than male ARMS
patients in uncorrected analyses. These differences became
significant when corrected for cannabis use (BPRS: b = !0.24,
P = 0.032; CAARMS: b = 0.33, P = 0.003, SANS: b = !0.22, P = 0.048).
However, when p-values were additionally adjusted for multiple
testing by using the FDR procedure, differences in negative
symptoms and general psychopathology were no longer signifi-
cant. There were no gender differences in ARMS patients with
regard to global functioning.
3.3. Gender differences in drug use and comorbidity
Table 3 shows the ORs for associations of gender with comorbid
drug use and affective and anxiety disorders for ARMS patients at
Table 2
Gender differences in psychopathology and functioning.
Rating scale Men
(n = 177)
Women
(n = 159)
N Coefficient [CI]
uncorrected
Coefficient [CI] corrected
cannabis use
P-value
uncorrected
P-value corrected for
cannabis use
P-value fully
correcteda
BPRS
BPRS Activation 3.8 (1.7) 3.5 (1.3) 319 !0.15 [-0.37;
0.07]
!0.10 [-0.32; 0.12] 0.191 0.396 0.700
BPRS Affect 7.7 (3.2) 8.1 (3.1) 319 0.02 [-0.20; 0.25] 0.06 [-0.16; 0.29] 0.848 0.613 0.866
BPRS Disorganization 4.0 (1.5) 3.6 (1.3) 319 !0.13 [-0.35;
0.09]
!0.09 [-0.32; 0.13] 0.241 0.412 0.700
BPRS Negative Symptoms 5.4 (2.7) 4.7 (2.0) 319 !0.22 [-0.44;
-0.01]
!0.24 [-0.46; -0.02] 0.046* 0.032* 0.181
BPRS Positive Symptoms 7.7 (3.3) 7.3 (3.0) 318 !0.09 [-0.31;
0.12]
!0.05 [-0.27; 0.17] 0.406 0.663 0.886
BPRS total score 44.2
(10.8)
43.0 (9.7) 319 !0.07 [-0.29;
0.14]
!0.03 [-0.24; 0.19] 0.498 0.798 0.928
CAARMS
CAARMS Behavioral change 7.8 (4.2) 8.2 (3.7) 332 0.07 [-0.15; 0.30] 0.11 [-0.11; 0.33] 0.520 0.336 0.700
CAARMS Cognitive change,
attention/concentration
3.2 (1.8) 3.1 (1.8) 332 0.03 [-0.20; 0.25] 0.04 [-0.19; 0.26] 0.804 0.740 0.925
CAARMS Emotional disturbance 3.2 (2.3) 3.1 (2.5) 330 !0.02 [-0.24;
0.20]
!0.04 [-0.26; 0.18] 0.862 0.751 0.925
CAARMS General
psychopathology
13.8
(6.6)
16.1 (6.0) 333 0.30 [0.08; 0.52] 0.33 [0.12; 0.56] 0.007** 0.003** 0.087
CAARMS Motor/physical
changes
2.1 (2.7) 2.3 (2.5) 329 0.18 [-0.04; 0.40] 0.19 [-0.03; 0.41] 0.107 0.088 0.312
CAARMS Negative symptoms 6.7 (3.7) 7.2 (3.1) 331 0.10 [-0.11; 0.34] 0.12 [-0.10; 0.35] 0.347 0.298 0.700
CAARMS Positive symptoms 10.0
(3.9)
9.7 (4.4) 334 0.00 [-0.21; 0.21] 0.02 [-0.20; 0.23] 0.993 0.862 0.985
GAF
GAF Disability, impairment 55.6
(12.4)
55.2 (12.4) 328 0.05 [-0.18; 0.26] 0.01 [-0.22; 0.22] 0.682 0.960 1.000
GAF Symptoms 54.9
(10.3)
55.3 (10.1) 313 0.07 [-0.16; 0.29] 0.05 [-0.18; 0.28] 0.570 0.678 0.886
MADRS
MADRS Detachment 6.4 (3.2) 6.2 (3.2) 323 !0.07 [-0.29;
0.15]
!0.07 [-0.29; 0.16] 0.546 0.568 0.846
MADRS Negative Thoughts 3.0 (2.3) 3.2 (2.1) 322 0.07 [-0.15; 0.31] 0.10 [-0.12; 0.35] 0.528 0.374 0.700
MADRS Neurovegetative 5.0 (3.1) 5.4 (3.3) 323 0.14 [-0.09; 0.36] 0.17 [-0.06; 0.39] 0.228 0.147 0.410
MADRS Sadness 4.2 (2.7) 4.4 (2.8) 323 0.03 [-0.19; 0.26] 0.03 [-0.19; 0.26] 0.759 0.773 0.927
MADRS total score 18.6
(9.3)
19.2 (9.1) 323 0.06 [-0.16; 0.28] 0.08 [-0.14; 0.31] 0.581 0.464 0.724
SANS
SANS Affective Flattening 4.0 (4.7) 2.9 (4.2) 325 !0.20 [-0.42;
0.02]
!0.22 [-0.45; 0.00] 0.073 0.048* 0.238
SANS Alogia 1.8 (2.5) 1.0 (2.1) 325 !0.17 [-0.38;
0.04]
!0.17 [-0.39; 0.04] 0.120 0.121 0.381
SANS Asociality-Anhedonia 6.1 (4.6) 5.1 (4.0) 324 !0.16 [-0.39;
0.06]
!0.18 [-0.41; 0.05] 0.157 0.125 0.381
SANS Avolition-Apathy 3.5 (2.9) 3.4 (2.6) 325 0.06 [-0.15; 0.27] 0.08 [-0.13; 0.30] 0.576 0.449 0.724
SANS Inattention 0.9 (1.5) 1.1 (1.7) 321 0.20 [-0.02; 0.41] 0.20 [-0.02; 0.41] 0.069 0.079 0.312
SANS total score 16.4
(11.5)
13.5 (10.8) 325 !0.14 [-0.35;
0.08]
!0.15 [-0.37; 0.07] 0.216 0.191 0.471
YMRS
YMRS total score 4.4 (5.1) 3.3 (3.8) 316 !0.17 [-0.38;
0.05]
!0.09 [-0.30; 0.12] 0.131 0.415 0.700
BPRS: Brief Psychiatric Rating Scale; CAARMS: Comprehensive Assessment of At-Risk Mental State; GAF: Global Assessment of Functioning; MADRS: Montgomery Åsberg
Depression Rating Scale;
SANS: Scale for the Assessment of Negative Symptoms; YMRS: Young Mania Rating Scale; CI = 95% Confidence Interval.
a P-value corrected for cannabis use and multiple testing.
* P < 0.05.
** P < 0.01.
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baseline. Unadjusted ORs indicate that men had a significantly
higher proportion of current cannabis users (OR, 0.53; 95% CI 0.32
to 0.88; P = 0.015) and a higher current frequency of cannabis use
than women (P = 0.008).
With regard to broad diagnostic categories, women were
significantly more often diagnosed with any lifetime affective
disorder (OR, 1.72; 95% CI 1.05–2.81; P = 0.032) and any current
anxiety disorder (OR, 1.66; 95% CI 1.04–2.64; P = 0.034). With
regard to specific diagnoses, women were more frequently
diagnosed with a past major depressive episode (OR, 1.78; 95%
CI 1.11–2.88; P = 0.018), a current panic disorder with (OR, 2.57; 95%
CI 1.14–5.81; P = 0.024) and without agoraphobia (OR, 2.00; 95% CI
1.12–3.55; P = 0.019), current specific phobia (OR, 4.26; 95%
CI 1.90–9.51; P = < 0.001) and current PTSD (OR, 2.25; 95%
CI 1.07–4.74; P = 0.033). However, when adjusted for multiple
testing, only current specific phobia remained significantly
associated with gender (P = 0.031).
4. Discussion
The current study investigated gender differences in socio-
demographic variables, symptomatology, drug use, comorbidity
(i.e. substance use, affective and anxiety disorders) and global
functioning in 336 ARMS patients presenting for the first time at an
early detection service in a multi-national study. Unadjusted
analyses indicated higher severity of negative symptoms (i.e. BPRS
negative symptoms, SANS affective flattening) and current
cannabis use in men while women showed higher severity of
general psychopathology (CAARMS) and suffered more from
comorbid affective (i.e. lifetime affective disorders, past major
depressive episode) and anxiety disorders (e.g. panic, panic with
agoraphobia, specific phobia, PTSD). However, when corrected for
multiple testing and confounding variables, these differences were
no longer significant except for higher lifetime rates of specific
phobia in women.
Regarding sociodemographic variables, our results are in
agreement with an earlier study on ARMS patients [11] with the
exception of age and living situation. While Rietschel et al. [11]
found no gender difference in age, the current study found male
ARMS patients to be significantly older than female ARMS patients
but only if statistically not corrected for multiple testing. Rietschel
et al. [11] suggest that male ARMS patients are living more
frequently with their parents or other relatives than female ARMS
patients whereas the present study did not find any significant
Fig. 1. Standardized mean differences (d) and 95% confidence intervals of the Brief Psychiatric Rating Scale (BPRS), Comprehensive Assessment At-Risk Mental State
(CAARMS), Global Assessment of Functioning (GAF), Montgomery-Åsberg Depression Rating Scale (MADRS), Scale for the Assessment of Negative Symptoms (SANS) and
Young Mania Rating Scale (YMRS). The bold vertical line at zero represents the severity of symptomatology in men. Differences are significant if the 95% confidence
interval (horizontal line) does not overlap with zero.
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gender differences. This finding may be due to the slightly lower
average age in our sample. Another possibility is that this gender
difference is dependent on the country or region the sample is
taken from.
Regarding psychopathology, our findings were in line with a
previous study of our own group that reported no gender
differences in psychopathology, neither in ARMS nor in FEP
patients, when corrected for multiple testing [26]. Furthermore,
Willhite et al. [27] also found no significant gender differences in
ratings of any of the symptoms of the Scale of Prodromal
Symptoms (SOPS) in high-risk patients. A possible explanation
may be that gender differences in the symptoms are so small that
they can only be reliably detected in studies with very high
statistical power (i.e. in very large datasets or in meta-analyses).
However, such small effects would likely not be clinically
meaningful.
Regarding drug use and comorbidity, male ARMS patients
showed higher rates of current cannabis use and frequency of
intake in unadjusted but not in adjusted analyses compared to
female ARMS patients. This finding is in line with a previous study
of our own group [26] and others that report no gender differences
regarding substance abuse in the prodromal phase of schizophre-
nia [2]. However, higher rates of substance abuse in men are found
in the general population [7] and in schizophrenia in particular [2].
Our finding of higher rates of comorbid affective and anxiety
disorders in female ARMS patients contradicts a recent study on
ARMS patients, which has found no gender differences for affective
and anxiety disorders [11]. However, an earlier study found greater
rates of current depression and social anxiety in high-risk women
compared to men [28]. Furthermore, Pruessner et al. [29] also
found more depressive symptoms in high-risk women, but these
differences did not withstand correction for multiple testing. An
explanation may be that the self-report questionnaires used in the
study of Rietdijk et al. [28] have led to an overestimation of the
number of patients with an anxiety disorder or depression. Most
importantly, our results are in line with epidemiological studies on
depression and anxiety in the general population, which found
female/male prevalence ratios of 2:1, respectively [30,31]. ARMS
patients in this respect thus do not seem to differ from the general
population.
Our finding of no gender difference in terms of level of
functioning is in accordance with previous studies [2].
A strength of our study is that we examined gender differences
with several, well established instruments to assess a broad range
of symptomatology. Rater trainings have been used to ensure that
all raters administering the rating scales in the same way.
Furthermore, the multicentre design of our study might have
contributed to heterogeneity in our sample through, for example,
Table 3
Gender differences in drug use and comorbidity.
SCID Diagnosis Men (n = 177) Women (n = 159) N Odds ratio [CI] P-value uncorrected P-value correcteda
Drug use
Cannabis current use 56 (31.6%) 31 (19.5%) 336 0.53 [0.32; 0.88] 0.015* 0.175
Cannabis current frequency 336 0.008** 0.168
none 121 (68.4%) 128 (80.5%)
only once or twice 2 (1.13%) 2 (1.26%)
a few times each year 7 (3.95%) 10 (6.29%)
a few times each month 12 (6.78%) 5 (3.14%)
(more than) once a week 9 (5.08%) 2 (1.26%)
every day 26 (14.7%) 12 (7.55%)
Cannabis lifetime dependence 36 (35.6%) 21 (26.9%) 179 0.72 [0.38; 1.40] 0.337 0.714
Amphetamines current use 30 (26.1%) 17 (21.0%) 196 0.74 [0.37; 1.46] 0.383 0.721
Amphetamines current abuse 2 (1.7%) 2 (2.5%) 196 1.43 [0.20; 10.48] 0.725 0.910
Amphetamines current dependence 2 (1.7%) 3 (3.7%) 196 2.23 [0.42; 11.97] 0.351 0.714
Cocaine current use 28 (24.3%) 11 (13.6%) 196 0.49 [0.23; 1.05] 0.069 0.312
Cocaine current abuse 2 (1.7%) 2 (2.5%) 196 1.52 [0.39; 5.84] 0.544 0.808
Cocaine current dependence 2 (1.7%) 1 (1.2%) 196 0.69 [0.16; 2.98] 0.619 0.829
Hallucinogens current use 16 (13.9%) 9 (11.1%) 196 0.81 [0.34; 1.89] 0.622 0.829
Hallucinogens current abuse 1 (0.9%) 1 (1.2%) 196 1.71 [0.42; 6.96] 0.456 0.788
Hallucinogens current dependence 1 (0.9%) 0 (0.0%) 196 0.00 [0.00; 0.00] 1.000 1.000
Affective disorders
Lifetime affective disorder 106 (59.9%) 122 (76.7%) 336 1.72 [1.05; 2.81] 0.032* 0.198
Current major depressive episode 48 (27.6%) 59 (38.6%) 327 1.52 [0.93; 2.46] 0.093 0.329
Past major depressive episode 71 (41.8%) 84 (57.5%) 316 1.78 [1.11; 2.88] 0.018* 0.175
Current dysthymic disorder 10 (6.0%) 10 (6.7%) 317 0.89 [0.37; 2.10] 0.782 0.945
Past manic episode 5 (3.0%) 7 (4.7%) 319 1.64 [0.54; 5.00] 0.385 0.721
Current hypomaniac episode 3 (1.9%) 1 (0.7%) 306 0.37 [0.04; 3.63] 0.395 0.721
Past hypomaniac episode 8 (4.8%) 9 (6.1%) 314 1.24 [0.47; 3.26] 0.665 0.868
Anxiety disorders
Current anxiety disorder 71 (40.1%) 94 (59.1%) 336 1.66 [1.04; 2.64] 0.034* 0.198
Current panic disorder 26 (15.7%) 44 (29.5%) 315 2.00 [1.12; 3.55] 0.019* 0.175
Current panic disorder with agoraphobia 9 (5.9%) 21 (15.3%) 290 2.57 [1.14; 5.81] 0.024* 0.194
Current agoraphobia without history of panic disorder 3 (1.7%) 3 (1.9%) 336 0.90 [0.18; 4.53] 0.895 0.988
Current social phobia 23 (13.6%) 38 (25.5%) 318 1.66 [0.92; 3.01] 0.092 0.329
Current specific phobia 7 (4.2%) 29 (19.3%) 318 4.26 [1.90; 9.51] <0.001*** 0.031*
Current generalized anxiety disorder 14 (8.5%) 22 (14.6%) 315 1.69 [0.84; 3.40] 0.144 0.419
Current obsessive compulsive disorder 16 (10.3%) 13 (9.3%) 295 0.99 [0.46; 2.13] 0.987 1.000
Current post traumatic stress disorder 11 (6.6%) 23 (15.3%) 317 2.25 [1.07; 4.74] 0.033* 0.198
SCID: Structured Clinical Interview for the Diagnostic Manual of Psychiatric Disorders DSM-IV; CI: 95% Confidence Interval.
a P-value corrected for multiple testing.
* P < 0.05.
** P < 0.01.
*** P < 0.001.
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different cultural modes of expression and accessibility and
potency of cannabis products in different study centres. We have
therefore included random intercepts that varied across study
centres in all our models. Finally, this is one of the first studies to
investigate gender differences in symptomatology in an ARMS
sample of this size.
However, although data were collected by well-trained
interviewers using standardized questionnaires and well-
established diagnostic criteria, this does not completely eliminate
possible gender-specific biases, e.g. of questionnaires and inter-
viewing techniques, of self-reporting, or interpreting patient
information, of applying diagnostic criteria or attributing diagnos-
tic labels [32]. Furthermore, this study concentrates on the age
group of 18–35 years with the consequence that especially boys,
who are at-risk state presumably before age 18 and women with
later age of onset are missed. An additional limitation could be that
our sample may not be representative for the overall population of
help-seeking patients since we do not know whether all ARMS
patients in the relevant catchment areas were searching help and
came to an early detection service. A recent study found a
significantly different gender distribution between ARMS and first
episode psychosis (FEP) patients with a greater proportion of males
in FEP cohorts than in clinical high-risk cohorts [33]. The authors
presume that ARMS men are probably less likely to be help-seeking
or less ‘literate’ of symptoms of mental illness which could lead to
an under-representation of men in existing clinical high-risk
services. Lastly, it should be noted that ARMS patients represent a
heterogeneous patient group with only about 20–35% developing
frank psychosis [34,35] and about one third having a clinical
remission within the first two years of the follow-up [36]. Hence,
gender differences reported in this study cannot be generalized to
patients being in true prodromal state for psychosis.
Taken together, our findings indicate that gender differences in
symptomatology – if present at all – are so small that they are likely
not to be clinically meaningful.
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Abstract
Background. Sex differences in cognitive functioning have long been recognized in schizophre-
nia patients and healthy controls (HC). However, few studies have focused on patients with an
at-risk mental state (ARMS) for psychosis. Thus, the aim of the present study was to investigate
sex differences in neurocognitive performance in ARMS patients compared with HC.
Methods.The data analyzed in this study were collected within themulticenter EuropeanGene–
Environment Interactions study (11 centers). A total of 343 ARMS patients (158 women) and
67 HC subjects (33 women) were included. All participants completed a comprehensive
neurocognitive battery. Linearmixed effectsmodels were used to explore whether sex differences
in cognitive functioning were present in the total group (main effect of sex) and whether sex
differences were different for HC and ARMS (interaction between sex and group).
Results.Women performed better in social cognition, speed of processing, and verbal learning
than men regardless of whether they were ARMS or HC. However, only differences in speed of
processing and verbal learning remained significant after correction for multiple testing.
Additionally, ARMS patients displayed alterations in attention, current IQ, speed of processing,
verbal learning, and working memory compared with HC.
Conclusions. Findings indicate that sex differences in cognitive functioning inARMS are similar
to those seen between healthy men and women. Thus, it appears that sex differences in cognitive
performance may not be specific for ARMS, a finding resembling that in patients with
schizophrenic psychoses.
Introduction
Sex differences in schizophrenia have been described in almost all features of the illness, including
incidence, prevalence, age at onset, symptomatology, course, and in the response to treatment,
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but only reliably established in age at onset and course [1]. Sex-related
differences in the illness coursemight be at least partiallymediated by
sex-related differences in cognitive functioning [2]. Reduced cognitive
performance is one of the core features of schizophrenia and an
important predictor of outcome [3]. Several studies have shown
neurocognitive deficits already in patients with a so-called at-risk
mental state (ARMS) for psychosis [4]. Furthermore, it has been
found that ARMS patients with later conversion to psychosis per-
formedworse at baseline in testsmeasuring attention/vigilance, speed
of processing, verbal and visual learning, and current and premorbid
IQ compared with patients who did not convert [4]. Consequently,
several studies have shown that the prediction of transition to psy-
chosis can be improved by including neurocognitive performance
measures into multivariable risk prediction models [4–8].
Cognitive performance is not only dependent on different stages
of psychotic disorders, but also on sex. In healthy controls (HC), it
is well established that women tend to perform better than men in
tasks measuring verbal abilities (d= 0.24; for meta-analysis, see
reference [9]), whereas men tend to outperform women on
visual–spatial tasks (d=0.45; for meta-analysis, see [9]) [10–
12]. Most studies indicate that these differences are also maintained
in patients with schizophrenic psychoses (for reviews, see refer-
ences [1,2]). Specifically, many studies have shown that women
diagnosed with schizophrenia have a better performance in verbal
learning and memory [1,13,14]. The female advantage in verbal
domains has also been found in patients with first-episode psycho-
sis (FEP), while men showed a better performance in tests of
reaction time, visual memory, and executive functions [1,10].
The impact of sex on cognitive functioning in ARMS has
received considerable attention in the literature in recent years. A
meta-regression analysis based on 19 studies assessing neuropsy-
chological performance in 1,188 ARMS patients (women, n= 523;
44%) and 1,029 HC (women, n=464; 45%) showed a trend-level
significance effect of sex on cognitive performance, with females
performing relatively better than males [15]. Our own group inves-
tigated sex differences in cognitive functioning in 118 ARMS
patients (women, n=45; 38%), 88 FEP patients (women, n= 32;
36%), and 86 HC (women, n= 41; 47%) [10]. Women performed
better in the domain of verbal learning and memory whereas men
showed a shorter reaction time during the working memory task
across all groups. However, these differences did not withstand
correction for multiple testing. Taken together, existing studies
indicate that female patients with psychotic disorders or being at
clinical high risk for psychosis do not perform better than males
over and above what we see in HC.
To the best of our knowledge, the present study is the first to
investigate sex differences in cognitive functioning in a large mul-
tinational sample of ARMS patients by using an extended neuro-
psychological battery and a healthy comparison group. The goal of
the study was to elucidate whether sex differences in cognitive
functioning differ between ARMS and HC subjects. Based on the
evidence above and our own findings, we expected a better perfor-
mance of women in the domain of verbal learning and memory
irrespective of group.
Methods
Setting and recruitment
The neuropsychological data analyzed in this study were collected
within the EUropean Gene–Environment Interactions (EU-GEI)
study, which aims to identify the interactive genetic, clinical, and
environmental determinants of schizophrenia [16]. EU-GEI is a
naturalistic prospective multicenter study that consisted of a base-
line and up to three follow-up time points (at 6months, 12months,
and 24months). Data were collected from May 1, 2010 to August
6, 2015. For the current analyses, only baseline data, that is, at intake
into the study, were used.
ARMS participants were recruited from 11 Early Detection and
Intervention Centers (London, Amsterdam, The Hague, Vienna,
Basel, Cologne, Copenhagen, Paris, Barcelona, Melbourne, Saõ
Paulo). They were referred to the EU-GEI study by primary health
care services, mental health professionals, or themselves or their
families.
Control participants were recruited by four of the above-
mentioned centers: the Institute of Psychiatry, Psychology, and
Neuroscience (IoPPN) in London, the Personal Assessment and
Crisis Evaluation Clinic inMelbourne, and theAmsterdamMedical
Center and Parnassia, The Hague. They were approached by tele-
phone and through advertisements at educational institutes. In
Melbourne, controls were additionally approached at community
centers/noticeboards and advertised via online platforms. Controls
were matched to the ARMS patients in terms of age, sex, migrant,
and ethnic status. All participants were screened with an inclusion/
exclusion checklist (see below).
The protocol of the EU-GEI study was approved by the institu-
tional review boards of all study sites. EU-GEI was conducted in
accordance with the Declaration of Helsinki. The Medical Ethics
Committees of all participating sites approved the study protocol.
Inclusion and exclusion criteria
Inclusion criteria for ARMS patients were: aged 14–45 (most of
them were between 18 and 35 years); being at-risk for psychosis as
defined by the comprehensive assessment of at-risk mental state
(CAARMS) [17]; adequate language skills corresponding to each
center; and consent to study participation. The exclusion criteria
were: prior experience of a psychotic episode of more than 1-week
as determined by the CAARMS [17] and Structural Clinical Inter-
view for Diagnostic and Statistical Manual of Mental Disorders
(DSMDisorders (SCID)) [18]; previous treatment with an antipsy-
chotic for a psychotic episode; and IQ< 60.
Inclusion criteria for controls were: aged 18–35; adequate lan-
guage skills local to each center; no evidence of current or past
psychosis (including treatment with antipsychotic medication).
Exclusion criteria for controls were similar to those for ARMS
participants. Additionally, controls were excluded if they met the
criteria for an ARMS status as defined by the CAARMS [17].
Detection procedure
The CAARMS was used to identify ARMS patients [17]. The
CAARMS is a semi-structured interview that encompasses psychotic
symptoms and a range of other psychopathological symptoms pre-
sent during the psychosis prodrome. Individuals were classified as
being in an ARMS for psychosis if they met at least one of the
following risk criteria: (i) attenuated psychotic symptoms (psychotic
symptoms subthreshold either in intensity or frequency); (ii) brief
limited psychotic symptoms (recent episode of brief psychotic symp-
toms that spontaneously resolved within 1week); or
(iii) vulnerability group (a first-degree relative with a psychotic
disorder or a diagnosis of a schizotypal personality disorder in
combination with a significant drop in functioning). The full criteria
can be found elsewhere [17].
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Assessment of sociodemographic and clinical characteristics
Sociodemographic characteristics (e.g. age, sex, ethnicity) were
obtained using the modifiedMedical Research Council sociodemo-
graphic schedule [19]. Current cannabis frequency was assessed
with the modified version of the Cannabis Experience Question-
naire [20]. Data on comorbid affective and anxiety disorders were
assessed with the SCID [18]. Psychiatric medication (i.e., use of
antipsychotics, antidepressants, and sedatives) was obtained using
a medical history questionnaire, designed by the EU-GEI group.
The general level of functioning was assessed with the modified
version of the Global Assessment of Functioning (GAF) scale [21].
Classification and assessment of neuropsychology
Neuropsychological performance of each participant was assessed
by trained psychiatrists, psychologists, and research assistants. The
neuropsychological tests covered the following seven domains:
attention/vigilance, reasoning/problem solving, speed of proces-
sing, verbal learning, working memory, social cognition, and cur-
rent IQ. Test scores were assigned to cognitive domains in
accordance with Measurement and Treatment Research to
Improve Cognition in Schizophrenia (MATRICS) Consensus Cog-
nitive Battery (MCCB) [22]. Tests that are not part of the MCCB
were assigned to domains according to their most commonly used
function. The following measures were used to cover the cognitive
domains of interest:
• Attention/vigilance: Digit Span Forward subtest of the Wechsler
Adult Intelligence Scale-third edition (WAIS-III) [23];
• Reasoning/problem solving: Beads Task [24];
• Speed of processing: Digit Symbol Test of the WAIS-III and the
Trail-Making Test parts A and B [25];
• Verbal Learning: Rey Auditory Verbal Learning Test [26];
• Working memory: Digit Span Backwards and Arithmetic sub-
tests of the WAIS-III [23];
• Social cognition: Degraded Affect Recognition Task [27] and the
Benton Facial Recognition Test [28]; and
• Current IQ: Block Design total raw score, the information total
raw score and the estimate of the total IQ of the shortenedWAIS-
III [23,29].
Assessment of psychopathology
The Brief Psychiatric Rating Scale expanded version (BPRS-E) [30]
was used to assess psychopathology. Sex differences were investi-
gated using the BPRS total score and the following subscales: BPRS
positive symptoms and BPRS negative symptoms [31].
Statistical analyses
All statistical analyses were performed using R [32]. Because obser-
vations were nonindependent, that is, observations from the same
center were more similar than observations from different centers,
sex differences were analyzed using linear mixed effects models
including sex and group (ARMS, HC) as a fixed effects factors and
randomly varying intercepts per center to account for the clustering
in the data. Linearmixed effects models were applied to evaluate the
main effects of sex and group (ARMS, HC) as well as their inter-
actions on cognitive functioning. Dependent variables were z-
transformed before inclusion to models and sex was included as a
binary variable with 0 and 1 describing men and women, respec-
tively. Thus, the regression coefficient for sex described the stan-
dardized mean difference (SMD) of women compared with men.
The results are presented with and without correction for multiple
testing. We used the false discovery rate procedure to adjust p-
values for multiple testing [33].
Results
Sample description
The sample of the present study consisted of 343 ARMS patients
(185 men, 158 women) and 67 HC subjects (34 men, 33 women).
Sociodemographic and clinical characteristics of our sample are
presented in Table 1. Cannabis use was more frequent in male
ARMS patients than female ARMS patients (30.51% vs. 18.46%
used cannabis at least a few times per year). With regard to
comorbid affective and anxiety disorders, female ARMS patients
showed more often a current anxiety disorder as well as posttrau-
matic stress disorders (PTSD) compared withmale ARMS patients.
There were no significant sex differences regarding any current
affective disorder (i.e., current depressive, manic, or hypomanic
episode and dysthymic disorder), neither for ARMS nor for
HC.With regard to psychopathology, male ARMS patients showed
significantly more severe BPRS “negative symptoms” (p=0.006)
than female ARMS patients. There were no sex differences in
ARMS and HC with regard to age, years of education, current
psychiatric medication, global functioning, BPRS “positive symp-
toms” and BPRS “total score.”
Effects of sex and diagnostic group on cognitive functioning
Means and standard deviations (SD) of the total group, ARMS, and
HC are presented in Table 2. Table 3 shows the results of the mixed
effects models using neurocognitive performance as the continuous
dependent variable and sex as well as group (ARMS, HC) as fixed
effects factors. SMDs of the neuropsychological measures are addi-
tionally presented in Figure 1.
In the combined sample of ARMS and HC, women recognized
more angry faces in the “Degraded Faces Affect Recognition” social
cognition task (p=0.034, b= 0.25), performed better in the “Digital
Symbol Coding” speed of processing task (p≤ 0.001, b=0.44) of the
WAIS-III, and remembered more words in the “Rey Auditory
Verbal Learning Test (RAVLT) delayed recall” (p=0.003, b=
0.41) and “RAVLT trials 1 to 5” (p=0.001, b=0.40) than men.
However, after correction for multiple testing, only the differences
in “Digital Symbol Coding” and the RAVLT measures remained
statistically significant.
Effects of diagnostic group are presented in Table 3. ARMS
patients performed significantly worse in all cognitive performance
scores, except in all scores of the problem solving and social
cognition tasks.
There was one statistically significant interaction between sex
and group (ARMS, HC) on the “WAIS-III Digit Span Backwards”
working memory task (p=0.011), which was due to a significantly
better performance of female HC compared with male HC (p<
0.026, b=!0.59) and a nonsignificantly worse performance of
female ARMS patients compared with male ARMS patients (p=
0.186, b=0.16). However, this sex " group interaction was no
longer significant after correction for multiple testing.
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The results did not change, when age or frequent cannabis use
(i.e., at least several times per week) were included as covariates.
Discussion
To the best of our knowledge, this is the first study investigating sex-
related neurocognitive performance differences in a multinational
ARMS sample of this size, using a comprehensive neuropsycholog-
ical battery and a healthy comparison group. In line with our
hypotheses, women showed superior performance in the domain
of verbal learning and memory independent of whether they were
ARMS patients orHC. Furthermore, women outperformedmen on
measures of speed of processing (i.e., Digital Symbol Coding total
raw score) and social cognition (i.e., Degraded Facial Affect Rec-
ognition Task (DFAR) angry faces total correct), whereas men
outperformed women on a trend-wise level on a task of working
memory (i.e., arithmetic total raw score). Additionally, our results
show that ARMS patients displayed alterations in attention, current
IQ, speed of processing, verbal learning, and working memory
compared with HC. However, we will not discuss this aspect any
further since it is not the focal point of the present study.
Finally, we found a sex" group interaction effect on working
memory (i.e., WAIS-III Digit Span Backwards), which was due to
a significantly better performance of female HC compared with
male HC and a nonsignificantly better performance of male
ARMS patients compared with female ARMS patients. However,
Table 1. Sociodemographic and clinical sample characteristics
ARMS HC
All Men Women p value
N
All Men Women p value
N(n = 343) (n = 185) (n = 158) (n = 67) (n = 34) (n = 33)
Age 22.4 (4.91) 22.7 (5.08) 22.1 (4.70) 0.210 343 22.9 (4.09) 23.0 (4.09) 22.7 (4.15) 0.720 67
Ethnicity 0.481 342 0.009** 67
White 245 (71.6%) 136 (73.5%) 109 (69.4%) 42 (62.7%) 23 (67.6%) 19 (57.6%)
Black 34 (9.94%) 18 (9.73%) 16 (10.2%) 10 (14.9%) 8 (23.5%) 2 (6.06%)
Mixed 28 (8.19%) 16 (8.65%) 12 (7.64%) 6 (8.96%) 0 (0.0%) 6 (18.2%)
Asian 11 (3.22%) 6 (3.24%) 5 (3.18%) 9 (13.4%) 3 (8.82%) 6 (18.2%)
North African 12 (3.51%) 6 (3.24%) 6 (3.82%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Other 12 (3.51%) 3 (1.62%) 9 (5.73%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Years of education 14.4 (3.07) 14.4 (3.28) 14.4 (2.83) 0.989 302 16.1 (2.79) 16.6 (2.97) 15.6 (2.55) 0.169 65
Cannabis current frequency 0.029* 334 0.081 67
None 247 (74.0%) 121 (68.4%) 126 (80.3%) 49 (73.1%) 22 (64.7%) 27 (81.8%)
Only once or twice 4 (1.20%) 2 (1.13%) 2 (1.27%) 1 (1.49%) 0 (0.0%) 1 (3.03%)
A few times each year 17 (5.09%) 7 (3.95%) 10 (6.37%) 4 (5.97%) 4 (11.8%) 0 (0.0%)
A few times each month 17 (5.09%) 12 (6.78%) 5 (3.18%) 7 (10.4%) 4 (11.8%) 3 (9.09%)
(More than) once a week 11 (3.29%) 9 (5.08%) 2 (1.27%) 3 (4.48%) 1 (2.94%) 2 (6.06%)
Every day 38 (11.4%) 26 (14.7%) 12 (7.64%) 3 (4.48%) 3 (8.82%) 0 (0.0%)
Antipsychotics currently 30 (11.8%) 15 (11.6%) 15 (11.9%) 1.000 255 0 (0.0%) 0 (0.0%) 0 (0.0%) 56
Antidepressants currently 82 (32.2%) 39 (30.2%) 43 (34.1%) 0.595 255 2 (3.57%) 0 (0.0%) 2 (7.14%) 0.491 56
Sedatives currently 15 (5.88%) 7 (5.43%) 8 (6.35%) 0.963 255 1 (1.79%) 0 (0.0%) 1 (3.57%) 1.000 56
Current affective disorder 127 (37.0%) 60 (32.4%) 67 (42.4%) 0.073 343 0 (0.0%) 0 (0.0%) 0 (0.0%) 67
Current anxiety disorder 166 (48.4%) 73 (39.5%) 93 (58.9%) 0.001** 343 5 (7.46%) 2 (5.88%) 3 (9.09%) 0.673 67
Current OCD 29 (9.70%) 16 (10.1%) 13 (9.29%) 0.975 299 0 (0.0%) 0 (0.0%) 0 (0.0%) 53
Current PTSD 34 (10.6%) 11 (6.40%) 23 (15.4%) 0.015* 321 0 (0.0%) 0 (0.0%) 0 (0.0%) 65
GAF disability, impairment 55.5 (12.3) 55.8 (12.4) 55.1 (12.1) 0.584 331 85.0 (8.98) 85.2 (8.15) 84.7 (9.92) 0.819 66
BPRS positive symptoms 7.48 (3.17) 7.67 (3.28) 7.27 (3.03) 0.254 323 3.17 (0.53) 3.13 (0.43) 3.21 (0.63) 0.550 59
BPRS negative symptoms 5.05 (2.40) 5.38 (2.65) 4.66 (2.02) 0.006** 324 3.00 (0.00) 3.00 (0.00) 3.00 (0.00) 0.325 59
BPRS total score 43.6 (10.2) 44.1 (10.6) 43.0 (9.67) 0.361 324 25.4 (2.61) 25.3 (2.24) 25.6 (3.01) 0.618 59
Abbreviations: ARMS, at-risk mental state; BPRS, Brief Psychiatric Rating Scale; GAF, Global Assessment of Functioning; HC, healthy controls; OCD, obsessive–compulsive disorder; PTSD, post-
traumatic stress disorder.
Continuous variables are described by means and standard deviation in brackets.
*p < 0.05.
**p < 0.01.
4 Stephanie Menghini-Müller et al.
29
only sex differences in the total group in speed of processing and
verbal learning remained significant after correction for multiple
testing.
With regard to verbal learning andmemory, our finding that the
female advantage is equally present in ARMS patients as in HC is in
line with previous research [1,15]. Furthermore, it corroborates the
findings of an earlier study of our own group that reported no
interaction effect between diagnostic group (i.e., ARMS, FEP, HC)
and verbal learning and memory [10].
Regarding processing speed, our finding that women perform
better than men is also consistent with earlier findings from the
general population [34,35] and patients with schizophrenia
[36,37]. To the best of our knowledge, this is the first study examining
sex differences in ARMS and healthy subjects by using well-
established tests to evaluate processing speed (i.e., TrailMaking Test,
WAIS-III Digit Symbol subtest). A previous study has investigated
sex-related cognitive performance differences inARMS, FEP andHC
but did not include tests specifically measuring processing speed
[10]. However, the authors found a shorter reaction time for men in
the working memory task independent of diagnostic group. They
explain the findings by a superior working memory performance
rather than generally enhanced processing speed in men as no sex
differences in reaction timeduring theContinuousPerformanceTest
and the Go/No-Go subtest of the Test of Attentional Performance
(TAP) were detected, while maintaining a comparable overall work-
ing memory performance level [10].
Table 2. Means and standard deviations of neuropsychological test data in ARMS patients and HC
Total group ARMS HC
All Men Women All Men Women All Men Women
(n = 410) (n = 219) (n = 191) (n = 343) (n = 185) (n = 158) (n = 67) (n = 34) (n = 33)
Attention
WAIS-III Digit Span Forward 9.69 (2.26) 9.66 (2.19) 9.73 (2.34) 9.51 (2.20) 9.50 (2.16) 9.51 (2.24) 10.7 (2.35) 10.5 (2.18) 11.0 (2.57)
Current IQ
Block Design total raw score 43.8 (15.2) 44.8 (15.2) 42.7 (15.3) 42.7 (15.5) 43.8 (15.1) 41.4 (15.8) 49.3 (12.9) 49.7 (14.8) 48.9 (11.0)
Estimate of total IQ 101 (17.9) 102 (18.7) 100 (17.0) 98.6 (16.8) 99.9 (17.6) 97.2 (15.9) 113 (18.1) 112 (20.5) 113 (15.7)
Information total raw score 16.9 (6.56) 17.5 (6.56) 16.2 (6.51) 16.3 (6.73) 17.1 (6.71) 15.5 (6.68) 19.4 (4.98) 19.4 (5.47) 19.4 (4.52)
Problem solving
Beads task draws to decision 6.62 (4.63) 6.90 (5.06) 6.31 (4.11) 6.54 (4.70) 6.74 (5.20) 6.33 (4.09) 7.02 (4.29) 7.73 (4.21) 6.22 (4.32)
Social cognition
BFR total correct 22.3 (2.33) 22.3 (2.24) 22.3 (2.43) 22.2 (2.32) 22.3 (2.24) 22.2 (2.42) 22.6 (2.36) 22.1 (2.31) 23.1 (2.36)
DFAR angry faces total
correct
10.2 (4.90) 9.67 (4.90) 10.7 (4.84) 10.5 (4.71) 9.99 (4.79) 11.0 (4.58) 8.61 (5.53) 7.94 (5.23) 9.30 (5.82)
DFAR frightened faces total
correct
8.59 (4.25) 8.17 (4.21) 9.07 (4.26) 8.80 (4.09) 8.26 (4.09) 9.43 (4.02) 7.50 (4.89) 7.68 (4.85) 7.31 (5.01)
DFAR happy faces total
correct
12.8 (5.08) 12.5 (5.23) 13.1 (4.89) 13.1 (4.78) 12.7 (5.07) 13.5 (4.38) 11.3 (6.23) 11.4 (6.01) 11.1 (6.54)
DFAR neutral faces total
correct
11.4 (4.84) 11.1 (4.95) 11.6 (4.72) 11.6 (4.57) 11.3 (4.76) 12.0 (4.31) 10.2 (5.97) 10.6 (5.92) 9.81 (6.09)
Speed of processing
Digital Symbol Coding total
raw score
73.1 (16.1) 70.2 (16.6) 76.4 (15.0) 71.7 (15.8) 69.2 (16.6) 74.5 (14.4) 80.1 (15.9) 75.2 (15.9) 85.0 (14.6)
TMT-A time to completion 29.6 (12.3) 30.7 (13.9) 28.4 (10.1) 30.2 (12.2) 31.2 (13.6) 29.1 (10.3) 26.6 (12.8) 28.1 (15.6) 25.0 (8.62)
TMT-B time to completion 70.3 (29.4) 74.6 (30.8) 65.7 (27.2) 73.2 (30.4) 77.9 (31.6) 68.0 (28.2) 56.3 (18.8) 58.0 (19.5) 54.4 (18.2)
Verbal learning
RAVLT delayed recall correct 10.7 (3.14) 10.2 (3.31) 11.4 (2.79) 10.6 (3.05) 10.0 (3.21) 11.2 (2.72) 11.4 (3.48) 10.9 (3.76) 12.0 (3.09)
RAVLT trial 1 correct 6.82 (2.02) 6.58 (1.93) 7.09 (2.09) 6.69 (1.99) 6.45 (1.86) 6.98 (2.11) 7.43 (2.04) 7.25 (2.14) 7.64 (1.93)
RAVLT trials 1–5 correct 52.2 (9.91) 50.6 (9.68) 54.0 (9.88) 51.3 (9.98) 49.9 (9.64) 53.1 (10.1) 56.3 (8.50) 54.1 (9.20) 58.7 (7.01)
Working memory
Arithmetic total raw score 13.5 (4.76) 14.1 (4.68) 12.8 (4.76) 13.1 (4.70) 13.8 (4.64) 12.3 (4.65) 15.5 (4.58) 15.9 (4.60) 15.1 (4.60)
WAIS-III Digit Span
Backwards
6.73 (2.27) 6.74 (2.28) 6.71 (2.27) 6.60 (2.19) 6.72 (2.30) 6.46 (2.06) 7.44 (2.58) 6.87 (2.21) 8.17 (2.87)
Abbreviations: ARMS, at-risk mental state; BFR, Benton Facial Recognition Test; DFAR, Degraded Facial Affect Recognition Task; HC, healthy controls; RAVLT, Rey Auditory Verbal Learning Test;
TMT, Trail Making Test; WAIS, Wechsler Adult Intelligence Scale.
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A strength of our study is that we examined sex differences
with well-established tests using the classification of the
MATRICS panel [22,38]. As the MCCB domains are well known
in schizophrenia research, this may help future studies to compare
sex-related cognitive performance differences in ARMS and
schizophrenic patients. Furthermore, this is the first study to
investigate sex differences in cognitive functioning in an ARMS
sample of this size.
However, there are some limitations to the present study that
need to be acknowledged. Our neuropsychological test battery was
originally selected to identify genetic and environmental interac-
tions in psychosis and not specifically to detect sex differences.
Accordingly, the test battery did not include other sensitive tasks
to detect sex differences such as visuo-spatial tasks. Additionally,
the domain of visual learning in the MATRICS consensus battery
was not covered. Furthermore, our control group was rather small
in comparison to the ARMS group, which reduced the statistical
power to detect interaction effects between sex and group. Finally,
it is important to note that sex-related cognitive performance
differences depend on a wide variety of conditions, for example,
the severity of symptoms and especially the fluctuation of estrogen
levels during the menstrual cycle in women (for review, see
reference [1]). There is evidence that high levels of estrogen at
the mid-luteal point are associated with better verbal memory and
diminished spatial ability [39]. Thus, it is possible that some
effects would have changed if we had measured women at a
specific time point during their monthly cycle. Unfortunately, in
our study no assessment of the time point during the monthly
cycle was performed.
Taken together, our findings indicate that sex differences in
cognitive functioning in ARMS patients are very similar to those
seen in the general population and in schizophrenia patients.
Table 3. p values and coefficients of fixed effects of mixed effects models
Group Sex Group" sex
p value p value corra Coef p value p value corra Coef p value p value corra Coef
Attention
WAIS-III Digit Span Forward <0.001*** 0.002** 0.55 0.441 0.530 0.11 0.467 0.782 0.22
Current IQ
Block Design total raw score <0.001*** <0.001*** 0.59 0.364 0.505 !0.12 0.561 0.782 0.15
Estimate of total IQ <0.001*** <0.001*** 0.88 0.658 0.697 !0.06 0.385 0.782 0.22
Information total raw score <0.001*** <0.001*** 0.61 0.329 0.493 !0.13 0.277 0.774 0.29
Problem solving
Beads task draws to decision 0.331 0.426 0.15 0.098 0.252 !0.23 0.659 0.782 !0.13
Social cognition
BFR total correct 0.143 0.198 0.22 0.201 0.329 0.18 0.124 0.705 0.45
DFAR angry faces total correct 0.435 0.489 !0.10 0.034* 0.151 0.25 0.695 0.782 0.09
DFAR frightened faces total correct 0.421 0.489 !0.11 0.409 0.525 0.10 0.112 0.705 !0.40
DFAR happy faces total correct 0.531 0.563 !0.08 0.547 0.615 0.07 0.301 0.774 !0.24
DFAR neutral faces total correct 0.922 0.922 !0.01 0.922 0.922 0.01 0.266 0.774 !0.27
Speed of processing
Digital Symbol Coding total raw score <0.001*** <0.001*** 0.63 <0.001*** 0.011* 0.44 0.157 0.705 0.37
TMT-A time to completion 0.017* 0.028* !0.36 0.162 0.291 !0.20 0.549 0.782 !0.17
TMT-B time to completion <0.001*** <0.001*** !0.65 0.122 0.261 !0.21 0.641 0.782 0.13
Verbal learning
RAVLT delayed recall correct 0.026* 0.040* 0.33 0.003** 0.019* 0.41 0.936 0.936 !0.02
RAVLT trial 1 correct 0.016* 0.028* 0.34 0.069 0.206 0.24 0.874 0.926 !0.04
RAVLT trials 1–5 correct <0.001*** <0.001*** 0.49 0.001** 0.011* 0.40 0.593 0.782 0.13
Working memory
Arithmetic total raw score <0.001*** <0.001*** 0.60 0.064 0.206 !0.24 0.580 0.782 0.14
WAIS-III Digit Span Backwards <0.001*** 0.002** 0.51 0.130 0.261 0.22 0.011* 0.197 0.75
Abbreviations: BFR, Benton Facial Recognition Test; coef, y-standardized regression coefficients of fixed effects; DFAR, Degraded Facial Affect Recognition Task; RAVLT, Rey Auditory Verbal
Learning Test; TMT, Trail Making Test; WAIS, Wechsler Adult Intelligence Scale.
aCorrected for multiple testing using Benjamini–Hochberg method.
*p < 0.05.
**p < 0.01.
***p < 0.001.
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Figure 1. Cognitive performance of women compared with men in at-risk mental state for psychosis individuals and healthy controls. The dotted horizontal line at zero represents
the performance of men. Differences are expressed in units of standard deviation and are significant if the 95% confidence interval (vertical line) does not overlap with zero.
Variables with a minus sign were reversed so that positive scores always represent good performance. Abbreviations: RAVLT, Rey Auditory Verbal Learning Test; TMT, Trail Making
Test; WAIS, Wechsler Adult Intelligence Scale.
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Aim: Gender differences in the current symptomatology of patients with psychotic disorders
have previously been described in the literature. However, it has not yet been investigated
whether gender differences exist in the very first self-perceived signs or symptoms of illness
onset. The aim of this study was to investigate this aspect in at-risk mental state (ARMS) and
first-episode psychosis (FEP) patients.
Methods: ARMS and FEP were recruited via the early detection of psychosis (FePsy) clinic
Basel, Switzerland. The Basel Interview for Psychosis (BIP) was used to retrospectively assess
the first 3 self-perceived signs and symptoms at illness onset. Differences between gender and
patient groups on single item and symptom cluster levels were analysed using logistic regres-
sion models.
Results: One-hundred-thirty six ARMS (91 men, 45 women) and 89 FEP patients (63 men,
26 women) could be recruited for this study. On a single item level, women more frequently
reported “unusual anxiety, fears” and men (at a trend level) “social withdrawal” as being among
their 3 first self-perceived symptoms, independent of diagnostic group. On the symptom clus-
ter level, women more frequently reported “increased worrying/anxiety” and (sub-threshold)
“hallucinations”, independent of diagnostic group. Problems with “thinking, concentration” were
reported more frequently by men in the ARMS group only.
Conclusion: Our results suggest that only few and relatively small gender differences exist in
the first self-perceived signs and symptoms. While men initially mainly notice negative/cogni-
tive symptoms, women first notice (sub-threshold) positive and affective symptoms.
KEYWORDS
BIP, gender, prodromal, psychopathology, psychotic disorder
1 | INTRODUCTION
Gender differences in schizophrenic psychoses have long been
reported and debated. Among the most replicated findings are differ-
ences in age of onset, which is earlier in men, while women have a
second peak of illness onset around menopause (Eranti, MacCabe,
Bundy, & Murray, 2013; Häfner, Maurer, Löffler, & Riecher-Rössler,
1993; Häfner, Riecher-Rössler, Fätkenheuer et al., 1991; Häfner,
Riecher-Rössler, Maurer et al., 1991)—a pattern suggested to be due
to the protective effects of high oestrogen levels in women before
menopause (Häfner, Riecher-Rössler, Maurer et al., 1991; Häfner,
Riecher-Rössler et al., 1993; Riecher-Rössler, 2017). Additionally,
recent reviews indicate a slightly increased incidence of schizophrenic
psychoses in men compared to women (van der Werf et al., 2014).
Moreover, men have been found to abuse substances more fre-
quently and to have less illness insight, worse treatment adherence
and poorer functional and social outcome (Abel, Drake, & Goldstein,
2010; Ochoa, Usall, Cobo, Labad, & Kulkarni, 2012). Gender differ-
ences have also been reported with respect to symptomatology,
although results in this area are inconsistent: While some studies
Received: 14 November 2016 Revised: 22 August 2017 Accepted: 8 November 2017
DOI: 10.1111/eip.12528
Early Intervention in Psychiatry. 2017;1–7. wileyonlinelibrary.com/journal/eip © 2017 John Wiley & Sons Australia, Ltd
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point towards more negative and cognitive symptoms in men and
more affective and positive psychotic symptoms in women (for an
overview see for example Waford et al., 2015), other studies either
could not confirm any gender differences (Barajas, Banos, & Ochoa,
2007; Bertani et al., 2012; Häfner, Riecher-Rössler, Fätkenheuer
et al., 1991) or found only few differences regarding illness behaviour
(Häfner, Riecher-Rössler, Fätkenheuer et al., 1991; Häfner, Riecher-
Rössler, Maurer et al., 1991).
In patients with an at-risk mental state (ARMS) for developing a
psychotic disorder, few studies have looked into potential gender differ-
ences in current symptomatology. A recent review by Barajas, Ochoa,
Obiols, and Lalucat-Jo (2015) concluded that gender differences are at
the most modest, the most replicated finding being more negative
symptoms in men. However, this conclusion was based on just 4 original
studies investigating gender differences regarding psychopathology pub-
lished up to that point (Cocchi et al., 2014; Corcoran et al., 2011;
Lemos-Giraldez et al., 2009; Willhite et al., 2008). Since then, further
studies have been published. A study by our own group (Gonzalez-
Rodriguez et al., 2014) in ARMS and first-episode psychosis (FEP)
patients revealed more positive psychotic symptoms in women (n = 43;
total sample n = 117) and more negative symptoms in men, which, how-
ever, did not withstand correction for multiple testing. Similar small gen-
der differences were reported in three further ARMS studies-more
negative symptoms in men (men n = 159, total sample n = 239;
Rietschel et al., 2015), more unusual experiences in women (women
n = 148, total sample n = 356; Waford et al., 2015) and more depres-
sive symptoms in women (women n = 53, total sample n = 129; Pruess-
ner et al., 2017). However, these studies did not correct for multiple
testing. On the other hand, a recent study by Kotlicka-Antczak
et al. (2016) in a Polish ARMS sample did not find any gender differ-
ences in symptoms (total sample n = 99, men n = 45). The inconsistent
findings of previous studies might furthermore be due to methodologi-
cal differences between the studies, as pointed out in a previous paper
(Gonzalez-Rodriguez et al., 2014). Thus, study samples are sometimes
quite selective and not representing all men and women with emerging
illness of a defined catchment area. As some studies only had small sam-
ple sizes, their statistical power might have been too low to detect gen-
der differences, which probably are of only small or moderate effect
size. Furthermore, the instruments used to assess the risk status and the
symptomatology, correction for multiple testing and adjustment for con-
founders varied between the studies, making it difficult to directly com-
pare the findings.
To extend the existing literature regarding gender differences in
symptoms of ARMS and FEP individuals, it might be interesting to
investigate what symptoms the patients in question notice them-
selves at the onset of the change in their psychological well-being.
These individually experienced changes will subsequently be referred
to as “first self-perceived symptoms.” Although several studies have
investigated current clinical symptoms in ARMS and FEP patients,
only few have retrospectively assessed the very first self-perceived
symptoms at illness onset (i.e., when the first decline in functioning
or well-being was noted by the patient), which has been estimated to
occur on average 4-5 years before first contact with psychiatry
(Riecher-Rössler et al., 2006). Among the first was the ABC study
(Häfner, Maurer et al., 1993; Häfner, Riecher-Rössler et al., 1993),
which found that female FEP patients most frequently reported rest-
lessness, depression and worrying as their initial symptoms, while
men most frequently reported trouble with thinking and concentra-
tion and anxiety when interviewed retrospectively with the instru-
ment for the retrospective assessment of the onset of schizophrenia
(IRAOS). Iyer et al. (2008) retrospectively also assessed first self-
perceived symptoms in FEP patients (using the Circumstances of
Onset and Relapse Schedule) and found symptoms of depression and
anxiety to be the most frequent signs. However, the authors did not
report gender-specific early symptoms. An earlier publication of our
own group (Aston et al., 2012) compared first self-perceived symp-
toms independent of gender in ARMS, FEP and depressive disorder
patients and found “loss of energy” and “difficulties concentrating” to
be the most frequent first self-perceived symptoms in the ARMS group,
while FEP patients reported “depression” and “irritability” as first self-
perceived symptoms. Furthermore, there was a considerable overlap of
the first self-perceived symptoms between the three groups.
To the best of our knowledge, no study has yet investigated gen-
der differences in first self-perceived symptoms in both ARMS and
FEP patients. Such investigations could improve not only our under-
standing of the aetiopathology of psychotic disorders but also their
early detection and treatment (Riecher-Rössler & Häfner, 2000; See-
man, 2013), which has become a major goal in psychiatry during the
last 2 decades (Riecher-Rössler & McGorry, 2016).
Thus, the aim of the present study was to contribute to this field
of research by investigating whether there are gender differences in
the very first self-perceived symptoms in male and female ARMS and
FEP patients. Based on the above-described literature, we hypothe-
sized that overall only small gender differences would be observable
in the first self-perceived symptoms of ARMS and FEP patients.
2 | METHODS
2.1 | Recruitment and screening procedure
ARMS and FEP patients were recruited for this study from March
2000 to March 2016 via the FePsy (Früherkennung für Psychosen;
English: early detection of psychosis) clinic of the University of Basel
Psychiatric Hospital, Switzerland. A detailed description of the FePsy
study procedure can be found elsewhere (Haller et al., 2009; Riecher-
Rössler et al., 2007). ARMS patients were identified using the Basel
Screening Instrument for Psychosis (BSIP) (Riecher-Rössler et al.,
2008), which is based on the PACE criteria (Yung et al., 1998) with
one additional inclusion category. Inclusion as ARMS patient required
one or more of the following: (1) “attenuated” psychotic symptoms,
(2) brief limited intermittent psychotic symptoms (BLIPS), (3) a first
degree relative with a psychotic disorder plus at least two risk factors
or (4) combination of unspecific risk factors according to the BSIP
(Riecher-Rössler et al., 2008). For inclusion, FEP patients had to fulfil
the transition criteria for psychosis according to Yung et al. (1998),
which were also assessed with the BSIP.
The following exclusion criteria were applied: age below
18 years, insufficient knowledge of German, IQ < 70, previous epi-
sode of schizophrenic psychosis (treated with antipsychotics above a
2 HEITZ ET AL.
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chlorpromazine equivalent of 2500 mg), psychosis clearly due to
organic reasons or substance abuse, or psychotic symptomatology
within a clearly diagnosed affective psychosis or borderline personal-
ity disorder (Riecher-Rössler et al., 2007).
All patients gave written informed consent. The Ethics Commit-
tee northwest/central Switzerland (EKNZ) approved the present
study.
2.2 | Assessment of first signs and symptoms and
duration of illness
The first signs and symptoms at illness onset as well as the duration
of illness (DUI) were assessed with the Basel Interview for Psychosis
(BIP; Riecher-Rössler et al., 2015). The BIP is a semi-structured inter-
view specifically developed to assess risk factors and indicators of
emerging psychosis as well as the temporal development of psychiat-
ric symptoms over the whole lifespan in ARMS and FEP patients. A
more detailed description of the BIP including its psychometric prop-
erties was described in a previous publication of our group (Riecher-
Rössler et al., 2015). The BIP contains the following 6 sections:
(1) social and physical development and family, (2) signs and symp-
toms, (3) vulnerability, (4) help-seeking behaviour, (5) illness insight
and (6) evaluation of the interview. In the item 2.2.2 of section 2,
patients are asked to openly name the first three symptoms they
noticed when they first experienced a drop in well-being or function-
ing. Only patients who could spontaneously recall at least one first
self-perceived change were included in the present study.
Each of the reported symptoms was subsequently categorized by
the rater to 1 of 62 pre-defined single symptoms and one of the fol-
lowing 14 symptom clusters: (1) Worries, agitation, anxiety; (2) Physi-
cal complaints; (3) Thinking, concentration; (4) Compulsions;
(5) Mood, emotions; (6) Sensitivity, suspiciousness; (7) Social isolation,
behavioural changes; (8) Supernatural, inexplicable experiences;
(9) Derealisation, depersonalization; (10) Hallucinations; (11) Delu-
sions; (12) Thought insertion, broadcasting and withdrawal; (13) Feel-
ing controlled by outside forces and (14) Problems with social
adjustment.
It should be noted that the clusters concerning hallucinations and
delusions capture sub-threshold as well as full-blown psychotic
symptoms.
DUI was determined with the BIP by assessing the date of the
first self-perceived sign or symptom and the date of first contact with
our early detection service, and by subsequently calculating the time
difference in months.
In addition, the Brief Psychiatric Rating Scale, Expanded version
(BPRS-E; Lukoff, KH, & Ventura, 1986; Ventura, Nuechterlein, Liber-
man, Green, & Shaner, 1993) and the Scale for the Assessment of
Negative Symptoms (SANS; Andreasen, 1989) were used to obtain
observer-based ratings of current symptomatology.
In the FePsy study, each patient is taken care of by a case-
manager (CM) who is either a psychologist or psychiatrist. All assess-
ments are organized by the responsible CM and all clinical interviews
are carried out by the CM. The following clinical interviews are part
of the FePsy study (in order of conduct): BSIP, structured clinical
interview for Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-V) (SCID) and BIP. To assure a proper conduct of
the interview, all CMs get an extensive training prior to their first
assessment. Furthermore, all CMs take part in monthly psychopathol-
ogy trainings including regularly the BIP. All trainings (pre-assessment
trainings and monthly psychopathology trainings) are led by an expe-
rienced clinical psychologist or the head psychiatrist.
2.3 | Statistical analyses
The socio-demographic variables (i.e., age and years of education)
as well as clinical characteristics (i.e., DUI, BPRS positive symptoms
according to the factor analysis of Velligan et al., 2005, SANS total
score) were compared between women and men in the ARMS, FEP
and total groups using t-tests, except for the comparison of dura-
tion of untreated illness, where analyses were conducted using
non-parametric Mann-Whitney U test, due to its non-normal
properties.
The most frequently reported first self-perceived symptoms were
listed on a single-item level. Logistic regression was used to compare
the most commonly reported single items in the total sample, with
presence of symptom (1 = yes/0 = no) as dependent variable and
gender and group as independent variables.
Due to their great number, the single items were subsequently
summarized on a cluster level in order to achieve more power in the
analysis and to facilitate the interpretation of the results. Differences
regarding the self-perceived symptoms on a cluster level were also
analysed in the total group using logistic regression, with presence of
symptom cluster (1 = presence of at least 1 symptom of the cluster/
0 = otherwise) as dependent variable and gender and group as inde-
pendent variables. In case of a significant interaction between gender
and group, gender differences were analysed separately for ARMS
and FEP patients. Complete case analysis was used to deal with miss-
ing values.
All data were analysed using the R environment for statistical com-
puting (R Core Team, 2016). The level of significance was set at .05.
3 | RESULTS
3.1 | Socio-demographic and clinical characteristics
During the recruitment period, 181 ARMS and 132 FEP patients
were recruited for the FePsy study. Of these, 136 ARMS (91 men,
45 women) and 89 FEP patients (63 men, 26 women) had completed
the BIP items regarding first self-perceived symptoms and thus were
included into this study. Excluded patients were not statistically dif-
ferent from included patients with regard to socio-demographic char-
acteristics. Socio-demographic and clinical characteristics of the final
sample are presented in Table 1. FEP patients were significantly older
than ARMS patients. However, age did not differ between men and
women, and there were no gender differences in years of education
and DUI.
In the total sample, men scored significantly higher on the SANS
total score than women. However, when ARMS and FEP patients
were analysed separately, this difference was not significant.
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Women had significantly higher scores in the BPRS Positive
Symptoms Scale than men, in the total sample as well as in the ARMS
subgroup.
3.2 | Most common first self-perceived symptoms:
Single-item level
The five most frequently reported first self-perceived signs and
symptoms in male and female ARMS and FEP patients are listed in
Table 2.
Logistic regression models for each of the five most commonly
reported symptoms revealed a significant main effect of gender in
the absence of a significant group x gender interaction for the symp-
tom “Unusual anxiety, fears” (P = .016; OR = 0.361 [0.154; 0.830]),
indicating that women reported this symptom more frequently than
men, regardless of diagnostic group.
Two more effects were significant on a trend level: First, there
was an interaction effect of group x gender for the item “Unusual dif-
ficulties concentrating” (P = .062; OR = 0.219 [0.043; 1.069]), which
was due to a non-significantly higher frequency of this symptom in
male ARMS compared to female ARMS patients (P = .356) and a
trend-wise significantly higher frequency of this symptom in female
FEP compared to male FEP patients (P = .098).
Second, there was a trend-wise main effect of gender for the
item “Withdrawal, avoiding contacts” (P = .056; OR = 2.510 [1.051;
7.373]), indicating that this item tended to be more frequently
reported by men than women, regardless of diagnostic group.
3.3 | Most common first self-perceived symptoms:
Symptom cluster level
Frequencies of the 14 first self-perceived symptom clusters of the
BIP in male and female ARMS and FEP patients are shown in
Figure 1.
In the logistic regression models, we found significant main
effects of gender in the absence of significant group x gender interac-
tions for the symptom clusters “Worries, agitation, anxiety” (P = .006;
OR = 0.395 [0.201; 0.769]) and “Hallucinations” (P = .047; OR =
0.294 [0.082; 0.974]), indicating that women reported these
symptom clusters more frequently than men independent of diagnos-
tic groups. However, as mentioned earlier, the cluster “Hallucinations”
includes full-blown as well as sub-threshold symptoms.
Furthermore, there was a significant group × gender interaction
for the symptom cluster “Thinking, concentration” (P = .012; OR =
0.152 [0.034; 0.652]), which was due to a significantly higher fre-
quency of this symptom cluster in male ARMS compared to female
ARMS patients (P = .014) and a non-significantly lower frequency in
male FEP compared to female FEP patients (P = .232).
We also found a significant main effect of diagnostic group for
the symptom cluster “Delusions” (P = .039; OR = 3.764 [1.190;
18.320]) in the absence of a significant group x gender interaction,
indicating that FEP patients reported this symptom cluster more fre-
quently than ARMS patients, independent of gender.
Additionally, there was a trend-wise main effect of diagnostic
group for the symptom cluster “Mood, emotions” (P = .059; OR =
0.542 [0.281; 1.007]), which was due to a higher frequency of this
symptom cluster in ARMS than in FEP patients.
4 | DISCUSSION
In this study, investigating for the first time gender differences in
both AMRS and FEP patients in the first self-perceived signs and
symptoms at illness onset, only few gender differences were found
with women reporting more frequently anxiety and positive psychotic
symptoms (single item “Unusual anxiety, fears”; symptom clusters
“Worries, agitation, anxiety” and (sub-threshold) “Hallucinations”) and
men reporting (trend-wise) more frequently negative and cognitive
symptoms (single items “Withdrawal, avoiding contacts” and in the
ARMS group “Unusual difficulties concentrating”; symptom cluster
“Thinking, concentration” only in the ARMS group).
When comparing ARMS and FEP independent of gender, the
symptom cluster “Delusions” was more frequently reported by FEP
than by ARMS patients while the symptom clusters “Mood, emotion”
was more frequently reported by ARMS than FEP patients.
These findings are consistent, at least in part, with the only previ-
ous study that has investigated gender differences in first self-
TABLE 1 Socio-demographic and clinical characteristics
All ARMS FEP
Women Men
P value N
Women Men
P value N
Women Men
P value NN = 71 N = 154 N = 45 N = 91 N = 26 N = 63
Age 28.3 (9.59) 26.3 (6.41) 0.102 225 26.5 (9.20) 25.3 (6.06) 0.400 136 31.4 (9.62) 27.7 (6.65) 0.081 89
Years of education 11.9 (3.10) 11.3 (2.76) 0.189 225 11.5 (2.83) 11.3 (2.60) 0.624 136 12.5 (3.48) 11.4 (3.00) 0.153 89
Duration of
untreated
illness [months]a
36.0 (76.1) 33.4 (61.7) 0.986 211 38.0 (72.0) 34.0 (60.0) 0.506 128 12.0 (55.3) 29.0 (68.0) 0.402 83
SANS total score 19.3 (15.7) 25.5 (17.0) 0.010* 218 18.6 (15.5) 24.4 (17.3) 0.056 133 20.6 (16.2) 27.2 (16.7) 0.105 85
BPRS positive
symptoms
10.3 (4.34) 8.98 (4.44) 0.036* 218 7.84 (2.44) 6.42 (2.21) 0.002* 132 14.4 (3.58) 12.8 (4.20) 0.065 86
Values are given in means; standard deviation in parentheses.
ARMS = at-risk mental state; FEP = first-episode psychosis.
a Values are given in median; interquartile range in parentheses.
*Significant at P < .05.
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perceived symptoms in FEP patients (Häfner et al., 1995). This study
also found higher rates of worrying among the very first self-
perceived symptoms in women and found men to report more trou-
ble with thinking and concentration as their first self-perceived symp-
tom, which we could only find in our male ARMS patients.
The above-reported gender differences in first self-perceived
symptoms was also reflected in our measures of current symptom-
atology (i.e., SANS and BPRS), in which men scored higher in negative
symptoms and women in (sub-threshold) positive symptoms. Further-
more, these results are in line with some previous studies that have
investigated gender differences in current symptomatology separately
in ARMS (Barajas et al., 2015; Pruessner et al., 2017; Rietschel et al.,
2015; Waford et al., 2015) and FEP patients (Moukas, Gourzis, Bera-
tis, & Beratis, 2010; Thorup et al., 2007). These studies also pointed
towards more negative symptoms in men and more (sub-threshold)
positive symptoms in women in ARMS and FEP patients. However,
as already discussed earlier, other studies could not confirm these
findings and did not reveal significant gender differences in the psy-
chopathology of ARMS and FEP patients (e.g., Bertani et al., 2012,
Gonzalez-Rodriguez et al., 2014, Kotlicka-Antczak et al., 2016). In an
attempt to synthesize the above findings, it might be speculated that
small gender differences in symptoms of the emerging disease exist,
with more negative and cognitive symptoms in men and more anxiety
or affective/ (sub-threshold) positive symptoms in women. However,
the size of this effect is probably small, such that differences in the
statistical power of the studies led to heterogeneous results. It should
be noted that it is possible that more pronounced gender differences
might emerge in FEP patients as compared to the ARMS patients due
to the more unspecific nature of this latter subsample (Fusar-Poli
et al. 2012).
Still, as shown for example by Walder et al. (2013), gender could
improve the prediction of psychosis by moderating the influence of
other important predictors, such as social functioning and positive
psychotic symptoms.
There are also several limitations of our study. First, the BIP
items that we used to measure first self-perceived signs and symp-
toms did not allow differentiating between sub-threshold and full-
blown psychotic symptoms. Hence, no final conclusion can be drawn
on whether the reported gender difference in the symptom cluster
“Hallucinations” was due to sub-threshold or full-blown symptoms.
However, given that psychoses usually do not start abruptly (i.e., with
full-blown symptoms), it is likely that the hallucinations that were
reported as first symptoms were mostly of sub-threshold severity.
Second, despite the attempt to capture first self-perceived symp-
toms already in the prodromal phase, it needs to be noted that on
average there were almost five years between the appearance of first
symptoms and the time point of the interview, which may have led
to a recall bias. However, as no gender difference was found in our
sample regarding DUI, it is not likely that this has influenced the
observed gender difference. Last, the smaller number of FEP patients
in the present study might have led to a lack of power to detect pos-
sible gender differences in this group compared to the larger ARMS
sample.
In interpreting these patterns, it should also be kept in mind that
awareness of the symptoms and insight into the illness might be
impaired in patients suffering from psychosis. According to a recent
review by Gerretsen et al. (2014) insight into schizophrenia is espe-
cially impaired in first-episode patients, while it is still mostly intact in
the premorbid phase. Furthermore, men and women may differ in
their symptom awareness, their illness insight and their willingness
and ability to report specific symptoms (Berger, Addis, Reilly, Syz-
dek, & Green, 2012; Riecher-Rössler, 2010). Thus, it is possible that
the few observed differences are at least partly due to reporting bias.
In conclusion, this study revealed small gender differences in
ARMS and FEP patients, with women reporting trend-wise less fre-
quently negative and cognitive symptoms and significantly more
often anxiety and (sub-threshold) positive symptoms than men. In
clinical practice, it might be important to also think of an emerging
psychotic disorder when women present with anxiety symptoms,
TABLE 2 Most frequently reported first self-perceived signs and
symptoms
Rank Symptom Frequency Percentage
ARMS women (N = 45)
1 Depressed, not able to feel joy 13 28.9
2 Unusual anxiety, fears 12 26.7
3 Loss of energy, slow, weak 8 17.8
4 Unusual difficulties concentrating 6 13.3
5 Sleeping problems for more than
1 week
5 11.1
5 Unusually sensitive, thin-skinned 5 11.1
5 Withdrawal, avoiding contacts 5 11.1
ARMS men (N = 91)
1 Depressed, not able to feel joy 23 25.3
2 Unusual difficulties concentrating 18 19.8
3 Withdrawal, avoiding contacts 17 18.7
4 Loss of energy, slow, weak 14 15.4
5 Unusual anxiety, fears 13 14.3
FEP women (N = 26)
1 Unusual difficulties concentrating 6 23.1
2 Depressed, not able to feel joy 5 19.2
2 Unusual anxiety, fears 5 19.2
4 Heard voices when nobody was
there
4 15.4
5 More nervous, restlessness 3 11.5
5 More sorrows, not able to stop
worrying
3 11.5
5 People tried to harm, poison, chase
or kill me
3 11.5
5 Sleeping problems for more than
1 week
3 11.5
5 Unusually frequent headaches,
other physical complaints
3 11.5
5 Unusually sensitive, thin-skinned 3 11.5
FEP men (N = 63)
1 Depressed, not able to feel joy 15 23.8
2 Withdrawal, avoiding contacts 14 22.2
3 Irritable, annoyed, unusually
quarrelsome
8 12.7
4 Loss of energy, retarded, weak 7 11.1
4 Unusually suspicious 7 11.1
ARMS = at-risk mental state; FEP = first-episode psychosis.
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because on one hand, these symptoms seem to mark more often the
beginning of a psychotic disorder in women than in men, and on the
other hand, because they might be more easily misattributed to a
depressive disorder in women due to the higher prevalence of depres-
sion in women. In men, on the other hand, social withdrawal should be
taken more seriously as a potential first sign of emerging psychosis.
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FIGURE 1 Frequencies and gender differences of the 14 first self-perceived symptom clusters of the Basel Interview for Psychosis (BIP) in both
diagnostic groups; ARMS = at-risk mental state; FEP = first-episode psychosis; *significant at P < .05
6 HEITZ ET AL.
41
Häfner, H., Riecher-Rössler, A., An Der Heiden, W., Maurer, K.,
Fatkenheuer, B., & Löffler, W. (1993). Generating and testing a causal
explanation of the gender difference in age at first onset of schizo-
phrenia. Psychological Medicine, 23(4), 925–940.
Häfner, H., Riecher-Rössler, A., Fätkenheuer, B., Hambrecht, M.,
Löffler, W., & An der Heiden, W. (1991). Sex differences in schizo-
phrenia. Psychiatria Fennica, 22, 123–156.
Häfner, H., Riecher-Rössler, A., Maurer, K., Fätkenheuer, B., Löffler, W.,
an der Heiden, W., … Stromgren, E. (1991). Geschlechtsunterschiede
bei schizophrenen Erkrankungen. [Sex differences in schizophrenic
diseases]. Fortschritte der Neurologie-Psychiatrie, 59(9), 343–360.
Haller, S., Borgwardt, S. J., Schindler, C., Aston, J., Radue, E. W., &
Riecher-Rössler, A. (2009). Can cortical thickness asymmetry analysis
contribute to detection of at-risk mental state and first-episode psy-
chosis? A pilot study. Radiology, 250(1), 212–221. doi: 250/1/212
[pii]. https://doi.org/10.1148/radiol.2501072153
Iyer, S. N., Boekestyn, L., Cassidy, C. M., King, S., Joober, R., & Malla, A. K.
(2008). Signs and symptoms in the pre-psychotic phase: Description
and implications for diagnostic trajectories. Psychological Medicine,
38(8), 1147–1156. https://doi.org/10.1017/s0033291708003152
Kotlicka-Antczak, M., Pawelczyk, T., Podgorski, M., Zurner, N.,
Karbownik, M. S., & Pawelczyk, A. (2016). Polish individuals with an
at-risk mental state: Demographic and clinical characteristics. Early
Intervention in Psychiatry. https://doi.org/10.1111/eip.12333
Lemos-Giraldez, S., Vallina-Fernandez, O., Fernandez-Iglesias, P.,
Vallejo-Seco, G., Fonseca-Pedrero, E., Paino-Pineiro, M., … Angel
Ortega-Ferrandez, J. (2009). Symptomatic and functional outcome in
youth at ultra-high risk for psychosis: A longitudinal study. Schizophre-
nia Research, 115(2–3), 121–129. https://doi.org/10.1016/j.schres.
2009.09.011
Lukoff, D. N., KH, & Ventura, J. (1986). Manual for the expanded brief
psychiatric rating scale. Schizophrenia Bulletin, 12, 594–602.
Moukas, G., Gourzis, P., Beratis, I. N., & Beratis, S. (2010). Sex differences
in prepsychotic "prodromal" symptomatology and its association with
positive and negative syndrome scale active phase psychopathology in
male and female patients. Comprehensive Psychiatry, 51(5), 546–551.
https://doi.org/10.1016/j.comppsych.2009.11.003
Ochoa, S., Usall, J., Cobo, J., Labad, X., & Kulkarni, J. (2012). Gender differ-
ences in schizophrenia and first-episode psychosis: A comprehensive
literature review. Schizophrenia Research and Treatment, 2012,
916198. https://doi.org/10.1155/2012/916198
Pruessner, M., Faridi, K., Shah, J., Rabinovitch, M., Iyer, S., Abadi, S., …
Malla, A. K. (2017). The Clinic for Assessment of Youth at Risk
(CAYR): 10 years of service delivery and research targeting the pre-
vention of psychosis in Montreal, Canada. Early Intervention in Psychia-
try, 11(2), 177–184. https://doi.org/10.1111/eip.12300
R Core Team (2016). A language and environment for statistical comput-
ing. R foundation for statistical computing. Vienna, Austria. Retrieved
from. https://www.R-project.org/
Riecher-Rössler, A. (2010). Prospects for the classification of mental disor-
ders in women. European Psychiatry, 25(4), 189–196. https://doi.org/
10.1016/j.eurpsy.2009.03.002
Riecher-Rössler, A. (2017). Oestrogens, prolactin, hypothalamic-pituitary-
gonadal axis, and schizophrenic psychoses. The Lancet Psychiatry, 4(1),
63–72. https://doi.org/10.1016/S2215-0366(16)30379-0
Riecher-Rössler, A., Ackermann, T., Uttinger, M., Ittig, S., Koranyi, S.,
Rapp, C., … Studerus, E. (2015). The Basel Interview for Psychosis (BIP):
Structure, reliability and validity. Fortschritte der Neurologie-Psychiatrie,
83(2), 99–108. https://doi.org/10.1055/s-0034-1398999
Riecher-Rössler, A., Aston, J., Ventura, J., Merlo, M., Borgwardt, S.,
Gschwandtner, U., & Stieglitz, R. D. (2008). Das Basel Screening
Instrument fur Psychosen (BSIP): Entwicklung, Aufbau, Reliabilität und
Validität. Fortschritte der Neurologie-Psychiatrie, 76(4), 207–216.
https://doi.org/10.1055/s-2008-1038155
Riecher-Rössler, A., Gschwandtner, U., Aston, J., Borgwardt, S., Drewe, M.,
Fuhr, P., … Stieglitz, R. D. (2007). The Basel early-detection-of-psychosis
(FePsy)-study - design and preliminary results. Acta Psychiatrica Scandi-
navica, 115(2), 114–125. https://doi.org/10.1111/j.1600-0447.2006.
00854.x
Riecher-Rössler, A., Gschwandtner, U., Borgwardt, S., Aston, J.,
Pfluger, M., & Rössler, W. (2006). Early detection and treatment of
schizophrenia: How early? Acta Psychiatrica Scandinavica, 113 (Suppl.
429), 73–80. https://doi.org/10.1111/j.1600-0447.2005.00722.x
Riecher-Rössler, A., & Häfner, H. (2000). Gender aspects in schizophrenia:
Bridging the border between social and biological psychiatry. Acta Psy-
chiatrica Scandinavica, 102 (Suppl. 407), 58–62.
Riecher-Rössler, A., & McGorry, P (2016). Early detection and intervention
in psychosis. State of the Art and Future Perspectives. In: Riecher-Röss-
ler A, Sartorius N (eds) Key Issues in Mental Health (Vol. 181). Karger
Publishers: Basel. DOI:10.1159/isbn.978-3-318-05621-1
Rietschel, L., Lambert, M., Karow, A., Zink, M., Muller, H., Heinz, A., …
Bechdolf, A. (2015). Clinical high risk for psychosis: Gender differ-
ences in symptoms and social functioning. Early Intervention in Psychia-
try, 11(4), 306–311. https://doi.org/10.1111/eip.12240
Seeman, M. (2013). Women and schizophrenia: New findings. Neuropsy-
chiatry, 3(4), 423–431. https://doi.org/10.2217/npy.13.55
Thorup, A., Petersen, L., Jeppesen, P., Ohlenschlaeger, J., Christensen, T.,
Krarup, G., … Nordentoft, M. (2007). Gender differences in young adults
with first-episode schizophrenia spectrum disorders at baseline in the
Danish OPUS study. The Journal of Nervous and Mental Disease, 195(5),
396–405. https://doi.org/10.1097/01.nmd.0000253784.59708.dd
van der Werf, M., Hanssen, M., Kohler, S., Verkaaik, M., Verhey, F. R., van
Winkel, R., … Allardyce, J. (2014). Systematic review and collaborative
recalculation of 133,693 incident cases of schizophrenia. Psychological
Medicine, 44(1), 9–16. https://doi.org/10.1017/s0033291712002796
Velligan, D., Prihoda, T., Dennehy, E., Biggs, M., Shores-Wilson, K.,
Crismon, M. L., … Shon, S. (2005). Brief psychiatric rating scale expanded
version: How do new items affect factor structure? Psychiatry Research,
135(3), 217–228. https://doi.org/10.1016/j.psychres.2005.05.001
Ventura, J. L., Nuechterlein, K. H., Liberman, R. P., Green, M., & Shaner, A.
(1993). Training and quality assurance with the brief psychiatric rating
scale: "The Drift Busters"; appendix 1 the brief psychiatric rating scale
(expanded version). International Journal of Methods in Psychiatric
Research, 3, 221–224.
Waford, R. N., MacDonald, A., Goines, K., Novacek, D. M., Trotman, H. D.,
Elaine, F. W., … McGlashan, T. H. (2015). Demographic correlates of
attenuated positive psychotic symptoms. Schizophrenia Research, 166
(1-3), 31–36. https://doi.org/10.1016/j.schres.2015.04.035
Walder, D. J., Holtzman, C. W., Addington, J., Cadenhead, K., Tsuang, M.,
Cornblatt, B., … Walker, E. F. (2013). Sexual dimorphisms and prediction
of conversion in the NAPLS psychosis prodrome. Schizophrenia Research,
144(1–3), 43–50. https://doi.org/10.1016/j.schres.2012.11.039
Willhite, R. K., Niendam, T. A., Bearden, C. E., Zinberg, J., O’Brien, M. P., &
Cannon, T. D. (2008). Gender differences in symptoms, functioning
and social support in patients at ultra-high risk for developing a psy-
chotic disorder. Schizophrenia Research, 104(1–3), 237–245. https://
doi.org/10.1016/j.schres.2008.05.019
Yung, A. R., Phillips, L. J., McGorry, P. D., McFarlane, C. A., Francey, S.,
Harrigan, S., … Jackson, H. J. (1998). Prediction of psychosis. A step
towards indicated prevention of schizophrenia. The British Journal of
Psychiatry. Supplement, 172(33), 14–20.
How to cite this article: Heitz U, Studerus E, Menghini-
Müller S, et al. Gender differences in first self-perceived signs
and symptoms in patients with an at-risk mental state and
first-episode psychosis. Early Intervention in Psychiatry.
2017;1–7. https://doi.org/10.1111/eip.12528
HEITZ ET AL. 7
42
     
 
Discussion 
The purpose of the present dissertation was to investigate sex and gender differences with 
regard to symptomatology, drug use, comorbidity, global functioning, neurocognition and 
first self-perceived signs and symptoms in patients with emerging psychosis. In the following 
sections the results of each publication will be discussed. 
 
 
  
 
    
  
    
 
 
 
    
   
Gender differences in symptomatology, drug use, comorbidity and functioning
In the first publication, gender differences in symptomatology, drug use, comorbidity (i.e. 
substance use, affective and anxiety disorders) and global functioning were investigated in a 
multinational sample of 336 ARMS patients (159 women) presenting for the first time at an
early detection service. Regarding psychopathology, our findings are in line with our hypoth- 
esis and previous studies among ARMS patients, which have reported no gender differences
in psychopathology (Gonzalez-Rodriguez et al., 2014; Willhite et al., 2008). A possible ex- 
planation could be that gender differences in the symptoms are so small that they can only be 
reliably detected in studies with very high statistical power (i.e. in very large datasets or in
meta-analyses). Our finding of no gender difference in terms of level of functioning is in line
with previous studies (Riecher-Rssler  et al., 2018). With regard to drug use and comorbidity, 
male ARMS patients showed higher rates of current cannabis use and frequency of intake in 
unadjusted but not in adjusted analyses compared to female ARMS patients. This finding is in
accordance with our hypothesis and other studies that report no gender differences regarding 
substance abuse in the prodromal phase of schizophrenia (Riecher-Rssle r et al.,
2018; Gonzalez-Rodriguez et al., 2014). Additionally, we found higher rates of comorbid af- 
fective and anxiety disorders in female ARMS patients, which is in conflict with a recent 
study that found no gender differences for affective and anxiety disorders (Rietschel et al., 
2015). However, others found greater rates of current depression (Rietdijk et al., 
2013; Pruessner et al., 2017) and social anxiety (Rietdijk et al., 2013) in high-risk women, but
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the differences reported by Pruessner et al. (2017) did not withstand correction for multiple 
testing. One possible explanation for the discrepancies in the results could be that the self-
report questionnaires used in the study of Rietdijk et al. (2013) have led to an overestimation 
of the number of patients with an anxiety disorder or depression. Most importantly, our results 
are in line with those of epidemiological studies on depression and anxiety in the general 
population (female/male rations of 2:1, respectively) (McLean et al., 2011; Riecher-Rössler et 
al., 2010b). Hence, it appears that ARMS patients in this respect do not differ from the gen-
eral population.  
 
 
 
  
  
 
 
  
 
Sex differences in cognitive functioning
In the second publication, sex-related neurocognitive performance differences have been in- 
vestigated in 343 ARMS patients (158 women) and 67 healthy individuals (33 women). All  
participants completed a comprehensive neurocognitive battery covering the domains of at- 
tention/vigilance, reasoning/problem solving, speed of processing, verbal learning and 
memory, working memory, social cognition and current IQ (for a detailed description, see 
publication 2). Our finding that women perform better in the domain of verbal learning and 
memory regardless of whether they were ARMS or HC is in line with our hypothesis and pre- 
vious research (Riecher-Rssler  et al., 2018; Fusar-Poli et al., 2012c). The results corroborate
the findings of an earlier study of our own group that reported no interaction effect between
diagnostic group (i.e. ARMS, FEP, HC) and verbal learning and memory (Ittig et al., 2015). 
Additionally, we found that women perform better than men in tasksmeasuring processing 
speed (i.e. Trail Making Test, WAIS-III Digit Symbol subtest) independent of group. This 
finding is consistent with earlier findings from the general population (e.g. Burns et al., 2005;
Jorm et al., 2004) and schizophrenia patients (Vaskinn et al., 2011; Torniainen et al., 2011) 
but in conflict with a previous study that reporteda shorter reaction time for men in the work- 
ing memory task independent of diagnosticgroup (i.e. ARMS, FEP, HC) (Ittig et al., 2015). A
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possible explanation for these inconsistent results could be that the latter did not include tests 
specifically measuring processing speed.  
 
 
 
      
 
 
 
 
    
      
  
    
   
 
 
  
Gender differences in first self-perceived signs and symptoms
The third publication Ô Gender differences in first self-perceived signs and symptoms in pa- 
tients with an at-risk mental state and first-episode psychosisÕ is the first study investigating
gender differences in both ARMS and FEP patients in the first self-perceived signs and symp- 
toms at illness onset. In total, 136 ARMS (45 women) and 89 FEP patients (26 women) com- 
pleted the BIP items regarding first self-perceived signs and symptoms and thus were includ- 
ed into the study. In line with our hypothesis,we found only few and relatively small gender 
differences in the first self-perceived signs and symptoms.Initially, men mainly noticed nega- 
tive and cognitive symptoms, while women first noticed (sub-threshold) positive and affective
symptoms. These findings are partly in line with the only previous study investigating first
self-perceivedsymptoms in FEP patients (H  fner et al., 1995b). The authors reported more
worrying in women and more trouble with thinking and concentration in men. Furthermore,
our results are in line with more recent studies investigating gender differences in the current
symptomatology in ARMS (Barajas et al., 2015; Pruessner et al., 2017; Rietschel et al., 2015; 
Waford et al., 2015) and FEP patients (Moukas et al., 2010; Thorup et al., 2007). These stud- 
ies also pointed towards more negative symptoms in men and more (sub-threshold) positive 
symptoms in women in ARMS and FEP patients. However, as already mentioned above, oth- 
er studies did not find any significant gender differences in the psychopathology of ARMS 
and FEP patients (e.g. Bertani et al., 2012; Gonzalez-Rodriguez et al., 2014; Kotlicka- 
Antczak et al., 2016). According to previous research and our own findings (see publication 
1), it might be speculated that small gender differences exist regarding symptomatology, with
more negative and cognitive symptoms in men and more anxiety or affective/(sub-threshold)
positive symptoms in women. However, the size of this effect is probably small, such that
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heterogeneous results might be explained by differences in the statistical power of the studies. 
It should also be noted that gender differences might be more pronounced in FEP patients 
compared to ARMS patients due to the larger diagnostic heterogeneity of the latter group 
(Fusar-Poli et al., 2012b).  
 
Conclusion and Perspectives 
In conclusion, the results of the first study indicate that gender differences in symptomatology 
and comorbidity in ARMS are similar to those seen in frank psychosis and in healthy con-
trols. However, these differences seem to be so small that they would only be reliably detect-
ed in studies with very high statistical power (i.e. in very large datasets or in meta-analyses). 
Such small effects would likely not be clinically meaningful. Future studies should investigate 
gender differences in symptomatology in studies with very high statistical power.  
The results of the second study suggest that sex differences in cognitive functioning in ARMS 
patients are similar to those seen in the general population and in schizophrenia patients. 
However, the effects were small which could also be explained by the fact that our neuropsy-
chological test battery was originally selected to identify gene-environment interactions in 
psychosis rather than detecting sex differences. Accordingly, our test battery did not include 
one of the most sensitive tasks to detect sex differences such as visuo-spatial tasks. Further-
more, future studies should also take the menstrual status into account since neuropsychologi-
cal performance has been shown to fluctuate with the monthly cycle (Riecher-Rössler et al., 
2018; Hampson, 1990). 
 
 
 
 
The third study revealed smal gender differences in the very first self-perceived signs and
symptoms of ARMS and FEP patients, with women reporting significantly more often anxiety
and (sub-threshold) positive symptoms and men reporting trend-wise more often negative and
cognitive symptoms. Clinically, it might be important to think of an emerging psychotic dis- 
order when women present with anxiety symptoms. On one hand, these symptoms seem to
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mark more often the beginning of a psychotic disorder in women compared to men and on the 
other hand, they might be misattributed to a depressive disorder in women because of the 
higher prevalence of depression in women. In men, however, social withdrawal might be a 
first sign of emerging psychosis and should be taken more seriously by clinicians.   
Altogether, the current dissertation reveals few sex and gender differences in all three publica-
tions. Gender differences regarding symptomatology in ARMS – if present at all – are small 
and similar to those found in frank psychosis and healthy controls. Similar sex differences 
regarding cognitive functioning can be found in the prodromal phase of psychosis, which also 
at least partly resembling those of the general population. Furthermore, the results from publi-
cation three again suggest that only few and relatively small gender differences exist in the 
first self-perceived signs and symptoms of the disease. More methodologically sound research 
should be done, investigating both sex (biological) and gender (psychosocial) to identify po-
tential differences in psychopathology and neurocognition in emerging psychoses.  
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